<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5041889</article-id><article-id pub-id-type="pmid">26943776</article-id><article-id pub-id-type="publisher-id">7853</article-id><article-id pub-id-type="doi">10.18632/oncotarget.7853</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tabb&#x000f2;</surname><given-names>Fabrizio</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pizzi</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kyriakides</surname><given-names>Peter W.</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ruggeri</surname><given-names>Bruce</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Inghirami</surname><given-names>Giorgio</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A5"><sup>5</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy</aff><aff id="A2"><sup>2</sup> Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA</aff><aff id="A3"><sup>3</sup> General Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padova, Padova, Italy</aff><aff id="A4"><sup>4</sup> Pre-Clinical Discovery Biology, Incyte Corporation, Wilmington, DE, USA</aff><aff id="A5"><sup>5</sup> Department of Pathology, and NYU Cancer Center, New York University School of Medicine, New York, NY, USA</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Giorgio Inghirami,</italic><email>ggi9001@med.cornell.edu</email></corresp></author-notes><pub-date pub-type="collection"><day>3</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>2</day><month>3</month><year>2016</year></pub-date><volume>7</volume><issue>18</issue><fpage>25064</fpage><lpage>25086</lpage><history><date date-type="received"><day>14</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>24</day><month>1</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2016 Tabb&#x000f2; et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p>Cancer biology relies on intrinsic and extrinsic deregulated pathways, involving a plethora of intra-cellular and extra-cellular components. Tyrosine kinases are frequently deregulated genes, whose aberrant expression is often caused by major cytogenetic events (e.g. chromosomal translocations). The resulting tyrosine kinase fusions (TKFs) prompt the activation of oncogenic pathways, determining the biological and clinical features of the associated tumors. First reported half a century ago, oncogenic TKFs are now found in a large series of hematologic and solid tumors. The molecular basis of TKFs has been thoroughly investigated and tailored therapies against recurrent TKFs have recently been developed. This review illustrates the biology of oncogenic TKFs and their role in solid as well as hematological malignancies. We also address the therapeutic implications of TKFs and the many open issues concerning their clinical impact.</p></abstract><kwd-group><kwd>tyrosine kinase fusions</kwd><kwd>translocations</kwd><kwd>signaling pathways</kwd><kwd>small molecule inhibitors</kwd><kwd>resistance mechanisms</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>The discovery of Philadelphia chromosome (Ph) in Chronic Myeloid Leukemia (CML) [<xref rid="R1" ref-type="bibr">1</xref>], the subsequent identification of the genes involved in this translocation [<xref rid="R2" ref-type="bibr">2</xref>] and the description of its molecular mechanisms [<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R4" ref-type="bibr">4</xref>] have marked a scientific milestone, which dramatically shaped our understanding of kinase-mediated oncogenesis.</p><p>Since these findings, many studies have investigated cell transformation via Tyrosine Kinase Fusions (TKFs). A recent appraisal of the literature shows that ~1000 independent studies have been published describing the oncogenic properties of TKFs. Recurrent kinase chimeras are detected in ~2-3% of human tumors and this frequency increases when non-recurrent fusions (4-5%) or cancer-associated abnormal karyotypes (5-7%) are considered [<xref rid="R5" ref-type="bibr">5</xref>]. TKFs do not represent the only cancer-associated gene derangement involving Tyrosine Kinases (TKs). During oncogenic transformation, TKs can indeed undergo a number of molecular impairments, including: (i) gene mutations; (ii) gene amplifications; (iii) chromosomal translocations; and (iv) non-fusion rearrangements (e.g. CRLF2 rearrangements in ALL) [<xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R7" ref-type="bibr">7</xref>]. All such Tyrosine Kinase (TK)-associated aberrations induce a huge variety of metabolic and signaling derangements, which ultimately lead to neoplastic transformation.</p><p>The widespread occurrence of TKFs in human cancers, their ability to synergistically fire multiple signaling pathways and their overall pivotal role in clinical oncology justify the many recent efforts to identify new anti-TKF target therapies. Of note, similar TKF-related pathways have been reported in different tumors; this constitutes the rationale for the use of similar therapies in tumors bearing the same molecular derangements. This approach is well represented by Ph-like leukemias, whose transcriptomes closely resemble those of conventional Ph-positive ALL, even in the absence of BCR-ABL translocations [<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R9" ref-type="bibr">9</xref>]. This model and its corresponding Patient Derived Tumor Xenografts (PDTX) allow the assessment of therapeutic agents targeting common molecular &#x0201c;hubs&#x0201d; [<xref rid="R10" ref-type="bibr">10</xref>]. This perspective is in line with the new &#x0201c;basket trial&#x0201d; era, where patients with different tumor types may be grouped together based on their tumors' mutational profile.</p><p>In this review, the role of TKFs in both hematologic and solid neoplasms will be discussed. Special attention will be devoted to the many open issues concerning the treatment of TKF-bearing neoplasms.</p></sec><sec id="s2"><title>STRUCTURES OF TKFS AND ROLE OF THE N-TERMINUS DOMAINS</title><p>Tyrosine kinases are the most common kinases and catalyze the transfer of a phosphate group from ATP to tyrosine residues. On a structural level, TK display a variety of modules dictating their cellular localization, function stability and response to therapy [<xref rid="R11" ref-type="bibr">11</xref>]. The enzymatic activity of these proteins relies on their TK domains (TKD), which are targeted by ATP-competitive and irreversible, covalent inhibitors [<xref rid="R12" ref-type="bibr">12</xref>]. Other important regions are the SH2 domains, the extracellular domains and remote allosteric sites, which can also be targeted by neutralizing drugs [<xref rid="R13" ref-type="bibr">13</xref>].</p><p>TKD are highly conserved modules, frequently composed by a N-terminal ATP-binding region and by a regulatory C-terminal domain. Upon activation, a cascade of events occurs, including ATP consumption, kinase dimerization, conformational changes, trans-autophosphorylation and oligo-complex formation. TK regulation is disrupted in oncogenic TKFs, which display constitutive dimerization due to loss of the inhibitory domains and forced oligodimerization of partner peptides [<xref rid="R14" ref-type="bibr">14</xref>]. Both inter- and intra-chromosomal rearrangements can lead to TKFs. Most break-points occur within introns and allow the synthesis of chimeric transcripts carrying the functional kinase domain and its flanking regions (Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>). Translocations involving TK membrane receptors frequently have breakpoints between exons coding for the juxta-membrane region. Though less frequent, the breaks can also split the trans-membrane domain upstream from the GXGXXG-coding exon. If protein products presenting the TK transmembrane domain localize to the cellular membrane, the exclusion of such a domain will localize the TK according to the properties of the translocation partner instead (Figure <xref ref-type="fig" rid="F1">1</xref>). In both cases, the natural TK ligand-binding site is lost. TKF involving intra-cytoplasmic kinases are also characterized by the loss of regulatory regions.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Tyrosine kinases fusion in hematological malignancies</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Kinase</th><th align="left" valign="middle" rowspan="1" colspan="1">Activating Mechanisms</th><th align="left" valign="middle" rowspan="1" colspan="1">Chromosomal translocation</th><th align="left" valign="middle" rowspan="1" colspan="1">Entity</th><th align="left" valign="middle" rowspan="1" colspan="1">Kinase inhibitor</th><th align="left" valign="middle" rowspan="1" colspan="1">Frequency (%)</th><th align="left" valign="middle" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>ALK</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to NPM1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;5)(p23;q35)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALCL, DLBCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">75-80, N/A</td><td align="left" valign="middle" rowspan="1" colspan="1">Morris <italic>et al.</italic> 1994, Adam <italic>et al</italic>. 2003</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to ALO17</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;17)(p23;q25)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Cools <italic>et al.</italic> 2002</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TGF</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;3)(p23;q21)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">2</td><td align="left" valign="middle" rowspan="1" colspan="1">Hernandez <italic>et al</italic>. 1999</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to MSN</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;X)(p32;q11-12)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Tort <italic>et al.</italic> 2001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TPM3</td><td align="left" valign="middle" rowspan="1" colspan="1">t(1;2)(q25;p23)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">12-18</td><td align="left" valign="middle" rowspan="1" colspan="1">Lamant <italic>et al</italic>. 1999</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TPM4</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;19)(p23;p13)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Meech <italic>et al</italic>. 2001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to ATIC</td><td align="left" valign="middle" rowspan="1" colspan="1">inv(2)(p23;q35)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">2</td><td align="left" valign="middle" rowspan="1" colspan="1">Ma <italic>et al.</italic> 2000</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to MYH9</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;22)(p23;q11.2)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Lamant <italic>et al.</italic> 2003</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TRAF1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;9)(p23;q33)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Feldman AL <italic>et al.</italic> 2013</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to CLTC1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;17)(p23;q23)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALCL, DLBCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">2, N/A</td><td align="left" valign="middle" rowspan="1" colspan="1">Touriol <italic>et al.</italic> 2000</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to SQSTM1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;5)(p23.1;q35.3)</td><td align="left" valign="middle" rowspan="1" colspan="1">DLBCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" rowspan="1" colspan="1">Takeuchi <italic>et al.</italic> 2010</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to SEC31A</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;4)(p24;q21)</td><td align="left" valign="middle" rowspan="1" colspan="1">DLBCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" rowspan="1" colspan="1">Bedwell <italic>et al.</italic> 2007</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to RANBP2</td><td align="left" valign="middle" rowspan="1" colspan="1">inv(2)(p23;q13)</td><td align="left" valign="middle" rowspan="1" colspan="1">AML</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Maesako <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>ABL</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to BCR</td><td align="left" valign="middle" rowspan="1" colspan="1">t(9;22)(q34;q11)</td><td align="left" valign="middle" rowspan="1" colspan="1">CML, B-ALL</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">85-90, &#x0003c;30</td><td align="left" valign="middle" rowspan="1" colspan="1">Klein et al. 1982</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TEL</td><td align="left" valign="middle" rowspan="1" colspan="1">t(9;12)(q34;p13)</td><td align="left" valign="middle" rowspan="1" colspan="1">AML</td><td align="left" valign="middle" rowspan="1" colspan="1">Dasatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Golub <italic>et al.</italic> 1996</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to NUP214</td><td align="left" valign="middle" rowspan="1" colspan="1">t(9;9)(q34.1;q34.3)</td><td align="left" valign="middle" rowspan="1" colspan="1">T-ALL, Ph-like ALL</td><td align="left" valign="middle" rowspan="1" colspan="1">Nitolinib</td><td align="left" valign="middle" rowspan="1" colspan="1">5</td><td align="left" valign="middle" rowspan="1" colspan="1">Graux <italic>et al.</italic> 2004, Roberts <italic>et al</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to EML1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(9;14)(q34;q32)</td><td align="left" valign="middle" rowspan="1" colspan="1">T-ALL</td><td align="left" valign="middle" rowspan="1" colspan="1">Nitolinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">De Keersmaecker <italic>et al</italic>. 2005</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to ZMIZ1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(9;10)(q34;q22)</td><td align="left" valign="middle" rowspan="1" colspan="1">B-ALL</td><td align="left" valign="middle" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Soler <italic>et al.</italic> 2008</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to RCSD1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(1;9)(q24;q34)</td><td align="left" valign="middle" rowspan="1" colspan="1">B-ALL</td><td align="left" valign="middle" rowspan="1" colspan="1">Dasatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Mustjoki <italic>et al</italic>. 2009</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to FOXP1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(3;9)(p12;q34)</td><td align="left" valign="middle" rowspan="1" colspan="1">B-ALL</td><td align="left" valign="middle" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Ernst T <italic>et al.</italic> 2011</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to SNX2</td><td align="left" valign="middle" rowspan="1" colspan="1">t(5;9)(q23;q34)</td><td align="left" valign="middle" rowspan="1" colspan="1">B-ALL</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Ernst T <italic>et al.</italic> 2011, Masuzawa <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to SEPT9</td><td align="left" valign="middle" rowspan="1" colspan="1">t(9;17)(q34;q25)</td><td align="left" valign="middle" rowspan="1" colspan="1">T-PLL</td><td align="left" valign="middle" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Suzuki <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to multiple partners</td><td align="left" valign="middle" rowspan="1" colspan="1">t(9;12)(q34;p13)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ph-like ALL</td><td align="left" valign="middle" rowspan="1" colspan="1">Dasatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Roberts <italic>et al.</italic> 2012, Roberts <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>ARG</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TEL</td><td align="left" valign="middle" rowspan="1" colspan="1">t(1;12)(q25;p13)</td><td align="left" valign="middle" rowspan="1" colspan="1">AML, aCML</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Golub <italic>et al.</italic> 1995</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>PDGFRa</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to FIP1L1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(4;12)(q23;p12)</td><td align="left" valign="middle" rowspan="1" colspan="1">HES</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">12</td><td align="left" valign="middle" rowspan="1" colspan="1">Cools <italic>et al</italic>. 2003</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to BCR</td><td align="left" valign="middle" rowspan="1" colspan="1">t(4;22)(q12;q11.2)</td><td align="left" valign="middle" rowspan="1" colspan="1">CEL, T-ALL, CML-like MPN</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Baxter <italic>et al.</italic> 2002, Yigit <italic>et al.</italic> 2015, Cluzeau <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TNKS2</td><td align="left" valign="middle" rowspan="1" colspan="1">t(4;10)(q12;q23.3)</td><td align="left" valign="middle" rowspan="1" colspan="1">MPN w/eosinophilia</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Chalmer <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to STRN</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;4)(p22;q12)</td><td align="left" valign="middle" rowspan="1" colspan="1">MPN w/eosinophilia</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Curtis <italic>et al.</italic> 2007</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to ETV6</td><td align="left" valign="middle" rowspan="1" colspan="1">t(4;12)(q23;p12)</td><td align="left" valign="middle" rowspan="1" colspan="1">MPN w/eosinophilia</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Curtis <italic>et al.</italic> 2007</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to KIF5B</td><td align="left" valign="middle" rowspan="1" colspan="1">t(4;10)(q12;p11)</td><td align="left" valign="middle" rowspan="1" colspan="1">MPN w/eosinophilia</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Score <italic>et al.</italic> 2006</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to CDK5RAP2</td><td align="left" valign="middle" rowspan="1" colspan="1">ins(9;4)(q33;q12q25)</td><td align="left" valign="middle" rowspan="1" colspan="1">CEL</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Walz <italic>et al.</italic> 2006</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>PDGFRb</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TEL</td><td align="left" valign="middle" rowspan="1" colspan="1">t(5;12)(q33;p13)</td><td align="left" valign="middle" rowspan="1" colspan="1">CMML</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">4</td><td align="left" valign="middle" rowspan="1" colspan="1">Golub <italic>et al.</italic> 1994</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to HIP1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(5;7)(q33;q11)</td><td align="left" valign="middle" rowspan="1" colspan="1">CMML</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">4</td><td align="left" valign="middle" rowspan="1" colspan="1">Ross <italic>et al.</italic> 1998</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to Rabaptin5</td><td align="left" valign="middle" rowspan="1" colspan="1">t(5;17)(q33;p13)</td><td align="left" valign="middle" rowspan="1" colspan="1">CMML</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Magnusson <italic>et al.</italic> 2001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to H4(D10S170)</td><td align="left" valign="middle" rowspan="1" colspan="1">t(5;10)(q33;q11-q21)</td><td align="left" valign="middle" rowspan="1" colspan="1">aCML</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Kulkarni <italic>et al.</italic> 2000</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to CEV14</td><td align="left" valign="middle" rowspan="1" colspan="1">t(5;14)(q33;q32)</td><td align="left" valign="middle" rowspan="1" colspan="1">AML</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Abe <italic>et al.</italic> 1997</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to Myomegalin</td><td align="left" valign="middle" rowspan="1" colspan="1">t(1;5)(q23;q33)</td><td align="left" valign="middle" rowspan="1" colspan="1">Eosinophilia</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Wilkinson <italic>et al.</italic> 2003</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to ATF71P</td><td align="left" valign="middle" rowspan="1" colspan="1">t(5;12)(q23;p13)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ph-like ALL</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Kobyashi <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to EBF1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(5;5)(q33.1;q33.3)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ph-like ALL</td><td align="left" valign="middle" rowspan="1" colspan="1">Dasatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Roberts <italic>et al.</italic> 2012, Roberts <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>FGFR1</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to multiple partners</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;8)(q12;p11)</td><td align="left" valign="middle" rowspan="1" colspan="1">EMS, AML</td><td align="left" valign="middle" rowspan="1" colspan="1">None</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Etienne <italic>et al.</italic> 2007</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to FOP</td><td align="left" valign="middle" rowspan="1" colspan="1">t(6; 8)(q27;p11)</td><td align="left" valign="middle" rowspan="1" colspan="1">MPN</td><td align="left" valign="middle" rowspan="1" colspan="1">None</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Lee <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to SQSTM1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(5;8)(q35;p11)</td><td align="left" valign="middle" rowspan="1" colspan="1">AML</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Nakamura Y <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>FGFR3</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TEL</td><td align="left" valign="middle" rowspan="1" colspan="1">t(4;12)(p16;p13)</td><td align="left" valign="middle" rowspan="1" colspan="1">PTCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Fiin23, NVP-BGJ398</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Maeda <italic>et al.</italic> 2005</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to IGH</td><td align="left" valign="middle" rowspan="1" colspan="1">t(4;14) (p16; q32)</td><td align="left" valign="middle" rowspan="1" colspan="1">CLL</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Geller <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TIF1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(7;8)(q34;p11)</td><td align="left" valign="middle" rowspan="1" colspan="1">MDS, CLL, AML</td><td align="left" valign="middle" rowspan="1" colspan="1">Fiin23, NVP-BGJ398</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Maeda <italic>et al.</italic> 2005</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>JAK2</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TEL</td><td align="left" valign="middle" rowspan="1" colspan="1">t(9;12)(p24;p13)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALL, CML-like</td><td align="left" valign="middle" rowspan="1" colspan="1">Ruxolitinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;5</td><td align="left" valign="middle" rowspan="1" colspan="1">Lacronique <italic>et al.</italic> 1997</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to OFD1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(X;9)(p22;p24)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALL</td><td align="left" valign="middle" rowspan="1" colspan="1">Jak2 inhibitors</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Yano <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to SPAG9</td><td align="left" valign="middle" rowspan="1" colspan="1">t(9;17)(p24;q21)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALL</td><td align="left" valign="middle" rowspan="1" colspan="1">Jak2 inhibitors</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Kavamura M <italic>et al</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to PAX5</td><td align="left" valign="middle" rowspan="1" colspan="1">t(9;9)(p13;p24)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALL</td><td align="left" valign="middle" rowspan="1" colspan="1">Jak2 inhibitors</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Nebral K <italic>et al.</italic> 2009</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to BCR</td><td align="left" valign="middle" rowspan="1" colspan="1">t(9;22)(p24;q11.2)</td><td align="left" valign="middle" rowspan="1" colspan="1">aCML</td><td align="left" valign="middle" rowspan="1" colspan="1">Ruxolitinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;5</td><td align="left" valign="middle" rowspan="1" colspan="1">Griesinger <italic>et al.</italic> 2005</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to multiple partners</td><td align="left" valign="middle" rowspan="1" colspan="1">t(9;12)(p24;p13)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ph-like ALL</td><td align="left" valign="middle" rowspan="1" colspan="1">Jak2 inhibitors</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Roberts <italic>et al.</italic> 2012, Roberts <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>NTRK3</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TEL</td><td align="left" valign="middle" rowspan="1" colspan="1">t(12;15)(p13;q25)</td><td align="left" valign="middle" rowspan="1" colspan="1">AML</td><td align="left" valign="middle" rowspan="1" colspan="1">None</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Knezevich <italic>et al.</italic> 1998</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>SYK</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TEL</td><td align="left" valign="middle" rowspan="1" colspan="1">t(9;12)(q22;p12)</td><td align="left" valign="middle" rowspan="1" colspan="1">MDS</td><td align="left" valign="middle" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Kanie <italic>et al.</italic> 2004</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to ITK</td><td align="left" valign="middle" rowspan="1" colspan="1">t(5;9)(q33;q22)</td><td align="left" valign="middle" rowspan="1" colspan="1">PTCL-NOS, AITL</td><td align="left" valign="middle" rowspan="1" colspan="1">None</td><td align="left" valign="middle" rowspan="1" colspan="1">17, &#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Streubel B <italic>et al</italic> 2006, Attygale et al 2013</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>TRKC</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TEL</td><td align="left" valign="middle" rowspan="1" colspan="1">t(12;15)(p13;q25)</td><td align="left" valign="middle" rowspan="1" colspan="1">AML and fibrosarcome</td><td align="left" valign="middle" rowspan="1" colspan="1">None</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Dobus <italic>et al.</italic> 2001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>FLT3</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to ETV6</td><td align="left" valign="middle" rowspan="1" colspan="1">t(12;13)(p13;q12)</td><td align="left" valign="middle" rowspan="1" colspan="1">HES</td><td align="left" valign="middle" rowspan="1" colspan="1">Sunitinib, Midostaurin, Lestaurtinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Vu <italic>et al.</italic> 2006</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>ETV6</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TEL</td><td align="left" valign="middle" rowspan="1" colspan="1">t(4;12)(p16;p13)</td><td align="left" valign="middle" rowspan="1" colspan="1">PTCL-NOS</td><td align="left" valign="middle" rowspan="1" colspan="1">Ruxolitinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Yagasaki <italic>et al.</italic> 2001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>CSF1R</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to SSBP2</td><td align="left" valign="middle" rowspan="1" colspan="1">t(5;5)(q14;q33)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ph-like ALL</td><td align="left" valign="middle" rowspan="1" colspan="1">Dasatinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Roberts <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>CRLF2</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to IGH</td><td align="left" valign="middle" rowspan="1" colspan="1">t(X;14)(p22;q32)/t(Y;14)(p11;q32)</td><td align="left" valign="middle" rowspan="1" colspan="1">Ph-like ALL</td><td align="left" valign="middle" rowspan="1" colspan="1">Jak2 inhibitors</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;5</td><td align="left" valign="middle" rowspan="1" colspan="1">Mullighan <italic>et al.</italic> 2009, Roberts <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>ROS1</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to NFKB2</td><td align="left" valign="middle" rowspan="1" colspan="1">t(6;10)(q22;q24)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Ros1 inhibitors</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Crescenzo <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to NCOR2</td><td align="left" valign="middle" rowspan="1" colspan="1">t(6;12)(q22;q24)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Ros1 inhibitors</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Crescenzo <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>TYK2</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to NFKB2</td><td align="left" valign="middle" rowspan="1" colspan="1">t(19;10)(p13;q24)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALCL</td><td align="left" valign="middle" rowspan="1" colspan="1">Tyk2 inhibitors</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Crescenzo et al. 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to NPM1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(19;5)(p13;q35)</td><td align="left" valign="middle" rowspan="1" colspan="1">LPDs</td><td align="left" valign="middle" rowspan="1" colspan="1">Tyk2 inhibitors</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Velusamy <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>LYN</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to NCOR</td><td align="left" valign="middle" rowspan="1" colspan="1">t(8;17)(q13;p11)</td><td align="left" valign="middle" rowspan="1" colspan="1">ALL</td><td align="left" valign="middle" rowspan="1" colspan="1">NA</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Yano <italic>et al.</italic> 2015</td></tr></tbody></table><table-wrap-foot><p><bold>Abbreviation:</bold> ALCL: anaplastic large cell lymphoma, AML: acute myeloid leukemia, B-ALL: B-cell acute lymphoblastic leukemia; T-ALL: T-cell acute lymphoblastic leukemia, Ph-like ALL: Philadelphia Chromosome like acute lymphoblastic leukemia, CEL: chronic eosinophilic leukemia, CML: chronic myeloid leukaemia; aCML: atypical chronic myeloid leukemia, CMML: chronic myelomonocytic leukemia, DLBCL: diffuse large B-cell lymphoma, EMS: 8p11 myeloproliferative syndrome, HES: hyper eosinophilic syndrome, LPDs: lymphoproliferative disorders, MDS: myelodysplastic syndrome, MPN: myeloproliferative neoplasm, PTCL-NOS: peripheral T-cell lymphoma not otherwise specified</p></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Tyrosine kinases fusions human in solid tumors</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Kinase</th><th align="left" valign="middle" rowspan="1" colspan="1">Activating Mechanisms</th><th align="left" valign="middle" rowspan="1" colspan="1">Chromosomal translocation</th><th align="left" valign="middle" rowspan="1" colspan="1">Entity</th><th align="left" valign="middle" rowspan="1" colspan="1">Kinase inhibitor</th><th align="left" valign="middle" rowspan="1" colspan="1">Frequency (%)</th><th align="left" valign="middle" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>ALK</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to ATIC</td><td align="left" valign="middle" rowspan="1" colspan="1">inv(2)(p23;q35)</td><td align="left" valign="middle" rowspan="1" colspan="1">IMT</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c; 5</td><td align="left" valign="middle" rowspan="1" colspan="1">Debiec-Rychter <italic>et al.</italic> 2003</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to CARS</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;11)(p23;p15)</td><td align="left" valign="middle" rowspan="1" colspan="1">IMT</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;5</td><td align="left" valign="middle" rowspan="1" colspan="1">Cools <italic>et al.</italic> 2002</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to CLTC</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;17)(p23;q23)</td><td align="left" valign="middle" rowspan="1" colspan="1">IMT</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;5</td><td align="left" valign="middle" rowspan="1" colspan="1">Bridge <italic>et al</italic>. 2001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to EML4</td><td align="left" valign="middle" rowspan="1" colspan="1">inv(2)(p21;p23)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib, Ceritinib, Alecitinib</td><td align="left" valign="middle" rowspan="1" colspan="1">2-5</td><td align="left" valign="middle" rowspan="1" colspan="1">Soda <italic>et al.</italic> 2007</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">BC, CRC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;5</td><td align="left" valign="middle" rowspan="1" colspan="1">Lin <italic>et al.</italic> 2009</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to FN1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;11)(q31;p15)</td><td align="left" valign="middle" rowspan="1" colspan="1">Soft tissue sarcoma</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">2-4</td><td align="left" valign="middle" rowspan="1" colspan="1">Ren <italic>et al.</italic> 2012</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to KIF5B</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;10)(p23;p11)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Takeuchi <italic>et al.</italic> 2009</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to KLC1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;14)(p23;q32)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;5</td><td align="left" valign="middle" rowspan="1" colspan="1">Jung <italic>et al.</italic> 2012</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to RANBP2</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;2)(p23;q13)</td><td align="left" valign="middle" rowspan="1" colspan="1">IMT</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;5</td><td align="left" valign="middle" rowspan="1" colspan="1">Ma <italic>et al.</italic> 2003</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to SEC31L1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;4)(p23;q21)</td><td align="left" valign="middle" rowspan="1" colspan="1">IMT</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;5</td><td align="left" valign="middle" rowspan="1" colspan="1">Panagopoulos <italic>et al.</italic> 2006</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to VCL</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;10)(p23;q22)</td><td align="left" valign="middle" rowspan="1" colspan="1">RCC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;3</td><td align="left" valign="middle" rowspan="1" colspan="1">Debelenko <italic>et al.</italic> 2011</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to SEC31A</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;4)(p23;q21)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Kim <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to STRN</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;2)(p23;p22)</td><td align="left" valign="middle" rowspan="1" colspan="1">Thyroid cancer</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">P&#x000e9;rot <italic>et al.</italic> 2014, Kelly <italic>et al.</italic> 2013</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Majewski <italic>et al.</italic> 2013</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to GTF2IRD1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;7)(p23;q11.23)</td><td align="left" valign="middle" rowspan="1" colspan="1">Thyroid cancer</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Stransky et al. 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TFG</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;3)(p23;q21)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">2</td><td align="left" valign="middle" rowspan="1" colspan="1">Rikova <italic>et al.</italic> 2007</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TPM1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;15)(p23;q22.2)</td><td align="left" valign="middle" rowspan="1" colspan="1">Bladder cancer</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Stransky <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TPM3</td><td align="left" valign="middle" rowspan="1" colspan="1">t(1;2)(q21;p23)</td><td align="left" valign="middle" rowspan="1" colspan="1">IMT</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">50</td><td align="left" valign="middle" rowspan="1" colspan="1">Lawrence <italic>et al.</italic> 2000</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TPM4</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;19)(p23;p13)</td><td align="left" valign="middle" rowspan="1" colspan="1">IMT</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;5</td><td align="left" valign="middle" rowspan="1" colspan="1">Lawrence <italic>et al.</italic> 2000</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to PTPN3</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;9)(p23;q31.3)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Jung <italic>et al.</italic> 2012</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to A2M</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;12)(p23;p13)</td><td align="left" valign="middle" rowspan="1" colspan="1">FLIT</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Onoda <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TPR</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;1)(p23;q31.1)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Choi <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to HIP1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;7)(p23;q11.23)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Hong <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to SQSTM1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;5)(p23;q35)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Iyevleva <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to DCTN1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;2)(p23;p13)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Iyevleva <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to SMEK2</td><td align="left" valign="middle" rowspan="1" colspan="1">t(2;2)(p23;p16.1)</td><td align="left" valign="middle" rowspan="1" colspan="1">CRC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Stransky et al. 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to CAD</td><td align="left" valign="middle" rowspan="1" colspan="1">inv(2)(p22-21p23)</td><td align="left" valign="middle" rowspan="1" colspan="1">CRC</td><td align="left" valign="middle" rowspan="1" colspan="1">Entrectinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Lee <italic>et al.</italic> 2015, Amatu <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>ROS1</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to CD74</td><td align="left" valign="middle" rowspan="1" colspan="1">t(5;6)(q32;q22)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;2</td><td align="left" valign="middle" rowspan="1" colspan="1">Bergethon <italic>et al.</italic> 2012</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to EZR</td><td align="left" valign="middle" rowspan="1" colspan="1">inv(6)(q22q25.3)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;2</td><td align="left" valign="middle" rowspan="1" colspan="1">Arai <italic>et al.</italic> 2013</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to GOPC</td><td align="left" valign="middle" rowspan="1" colspan="1">del(6)(q22q22.3)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;2</td><td align="left" valign="middle" rowspan="1" colspan="1">Rimkunas <italic>et al.</italic> 2012, Suehara <italic>et al.</italic> 2012</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">CCA</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Gu <italic>et al.</italic> 2011</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Ovarian Cancer</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Birch <italic>et al.</italic> 2011</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to LRIG3</td><td align="left" valign="middle" rowspan="1" colspan="1">t(6;12)(q22;q14.1)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;2</td><td align="left" valign="middle" rowspan="1" colspan="1">Takeuchi <italic>et al.</italic> 2012</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to SDC4</td><td align="left" valign="middle" rowspan="1" colspan="1">t(6;20)(q22;q12)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;2</td><td align="left" valign="middle" rowspan="1" colspan="1">Davies <italic>et al.</italic> 2012, Takeuchi <italic>et al.</italic> 2012</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to SLC34A2</td><td align="left" valign="middle" rowspan="1" colspan="1">t(4;6)(q15.2;q22)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;2</td><td align="left" valign="middle" rowspan="1" colspan="1">Davies <italic>et al.</italic> 2012</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Gastric cancer</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Lee <italic>et al.</italic> 2013</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TPM3</td><td align="left" valign="middle" rowspan="1" colspan="1">t(1;6)(q21.2;q22)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;2</td><td align="left" valign="middle" rowspan="1" colspan="1">Takeuchi <italic>et al.</italic> 2012</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TFG</td><td align="left" valign="middle" rowspan="1" colspan="1">t(6;3)(q22.1;q12.2)</td><td align="left" valign="middle" rowspan="1" colspan="1">IMT</td><td align="left" valign="middle" rowspan="1" colspan="1">Crizotinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Yamamoto <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>RET</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to CCDC6</td><td align="left" valign="middle" rowspan="1" colspan="1">inv10(q11;q21)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Cabozantinib, Vandetanib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;2</td><td align="left" valign="middle" rowspan="1" colspan="1">Wang <italic>et al.</italic> 2012</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Thyroid cancer</td><td align="left" valign="middle" rowspan="1" colspan="1">Cabozantinib, Vandetanib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;2</td><td align="left" valign="middle" rowspan="1" colspan="1">Celestino <italic>et al.</italic> 2012</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to KIF5B</td><td align="left" valign="middle" rowspan="1" colspan="1">inv(10)(p11;q11)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Cabozantinib, Vandetanib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;2</td><td align="left" valign="middle" rowspan="1" colspan="1">Ju <italic>et al.</italic> 2012</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to NCOA4</td><td align="left" valign="middle" rowspan="1" colspan="1">inv(10)(q11;q11)</td><td align="left" valign="middle" rowspan="1" colspan="1">Thyroid cancer</td><td align="left" valign="middle" rowspan="1" colspan="1">Cabozantinib, Vandetanib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;2</td><td align="left" valign="middle" rowspan="1" colspan="1">Rui <italic>et al</italic>. 2012</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to PRKAR1A</td><td align="left" valign="middle" rowspan="1" colspan="1">t(10;17)(q11.2;q23)</td><td align="left" valign="middle" rowspan="1" colspan="1">Thyroid cancer</td><td align="left" valign="middle" rowspan="1" colspan="1">Cabozantinib, Vandetanib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;2</td><td align="left" valign="middle" rowspan="1" colspan="1">Rui <italic>et al</italic>. 2012</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to ACBD5</td><td align="left" valign="middle" rowspan="1" colspan="1">inv(10)(p12.1;q11.2)</td><td align="left" valign="middle" rowspan="1" colspan="1">Thyroid cancer</td><td align="left" valign="middle" rowspan="1" colspan="1">Cabozantinib, Vandetanib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Hamatani <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>BRAF</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to KIAA1549</td><td align="left" valign="middle" rowspan="1" colspan="1">t(7;7)(q34;q34)</td><td align="left" valign="middle" rowspan="1" colspan="1">Brain tumors</td><td align="left" valign="middle" rowspan="1" colspan="1">BRAF/MEK inhibitors</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Tian <italic>et al.</italic> 2011</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to FAM131B</td><td align="left" valign="middle" rowspan="1" colspan="1">t(7;7)(q34;q34)</td><td align="left" valign="middle" rowspan="1" colspan="1">Brain tumors</td><td align="left" valign="middle" rowspan="1" colspan="1">BRAF/MEK inhibitors</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Cin <italic>et al.</italic> 2011</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to CEP89</td><td align="left" valign="middle" rowspan="1" colspan="1">t(7;19)(q34;q13)</td><td align="left" valign="middle" rowspan="1" colspan="1">Melanoma</td><td align="left" valign="middle" rowspan="1" colspan="1">BRAF/MEK inhibitors</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c; 5</td><td align="left" valign="middle" rowspan="1" colspan="1">Wiesner <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to LSM14A</td><td align="left" valign="middle" rowspan="1" colspan="1">t(7;19)(q34;q13)</td><td align="left" valign="middle" rowspan="1" colspan="1">Melanoma</td><td align="left" valign="middle" rowspan="1" colspan="1">BRAF/MEK inhibitors</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c; 5</td><td align="left" valign="middle" rowspan="1" colspan="1">Wiesner <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>FGFR1</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TACC1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(8;8)(p11.23;p11.22)</td><td align="left" valign="middle" rowspan="1" colspan="1">GBM</td><td align="left" valign="middle" rowspan="1" colspan="1">FGFR inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;3</td><td align="left" valign="middle" rowspan="1" colspan="1">Singh <italic>et al.</italic> 2012</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to BAG4</td><td align="left" valign="middle" rowspan="1" colspan="1">t(8;8)(p11.23;p11.23)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">FGFR inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Rui et al. 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>FGFR2</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to BICC1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(10;10)(q26;q21.1)</td><td align="left" valign="middle" rowspan="1" colspan="1">CCA</td><td align="left" valign="middle" rowspan="1" colspan="1">FGFR inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Yi-Mi <italic>et al.</italic> 2013</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to KIAA1967</td><td align="left" valign="middle" rowspan="1" colspan="1">t(10;8)(q26;p21.3)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">FGFR inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Yi-Mi et al. 2013</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to PPHLN1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(10;12)(q26;q12)</td><td align="left" valign="middle" rowspan="1" colspan="1">CCA</td><td align="left" valign="middle" rowspan="1" colspan="1">FGFR inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">45</td><td align="left" valign="middle" rowspan="1" colspan="1">Sia <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>FGFR3</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TACC3</td><td align="left" valign="middle" rowspan="1" colspan="1">del4(p16;p16)</td><td align="left" valign="middle" rowspan="1" colspan="1">GBM</td><td align="left" valign="middle" rowspan="1" colspan="1">FGFR inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;3</td><td align="left" valign="middle" rowspan="1" colspan="1">Singh <italic>et al.</italic> 2012, Bao <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Bladder cancer</td><td align="left" valign="middle" rowspan="1" colspan="1">FGFR inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;2</td><td align="left" valign="middle" rowspan="1" colspan="1">Williams <italic>et al.</italic> 2013</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">FGFR inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;2</td><td align="left" valign="middle" rowspan="1" colspan="1">Rui <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">ESCC</td><td align="left" valign="middle" rowspan="1" colspan="1">FGFR inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Yuan <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">NPC</td><td align="left" valign="middle" rowspan="1" colspan="1">FGFR inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;3</td><td align="left" valign="middle" rowspan="1" colspan="1">Yuan <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Cervical cancer</td><td align="left" valign="middle" rowspan="1" colspan="1">FGFR inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Carneiro <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>NTRK1</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TPM3</td><td align="left" valign="middle" rowspan="1" colspan="1">t(1;3)(q21;q11)</td><td align="left" valign="middle" rowspan="1" colspan="1">Thyroid cancer</td><td align="left" valign="middle" rowspan="1" colspan="1">TRKA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">7-8</td><td align="left" valign="middle" rowspan="1" colspan="1">Beimfohr <italic>et al.</italic> 1999</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">CRC</td><td align="left" valign="middle" rowspan="1" colspan="1">TRKA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Creancier <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">HGG</td><td align="left" valign="middle" rowspan="1" colspan="1">TRKA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Wu <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TPR</td><td align="left" valign="middle" rowspan="1" colspan="1">inv1(q23;q21)</td><td align="left" valign="middle" rowspan="1" colspan="1">Thyroid cancer</td><td align="left" valign="middle" rowspan="1" colspan="1">TRKA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Greco <italic>et al.</italic> 1999</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">CRC</td><td align="left" valign="middle" rowspan="1" colspan="1">TRKA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Creancier <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to MPRIP</td><td align="left" valign="middle" rowspan="1" colspan="1">t(1;17)(q21;p11)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">TRKA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;5</td><td align="left" valign="middle" rowspan="1" colspan="1">Vaishanvi <italic>et al.</italic> 2013</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to CD74</td><td align="left" valign="middle" rowspan="1" colspan="1">t(1;5)(q21;q32)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">TRKA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;5</td><td align="left" valign="middle" rowspan="1" colspan="1">Vaishanvi <italic>et al.</italic> 2013</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to RABGAP1L</td><td align="left" valign="middle" rowspan="1" colspan="1">t(1;1)(q21;q25.1)</td><td align="left" valign="middle" rowspan="1" colspan="1">CCA</td><td align="left" valign="middle" rowspan="1" colspan="1">TRKA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Ross <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to SQSTM1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(1;5)(q21;q35)</td><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Entrectinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Farago <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to LMNA</td><td align="left" valign="middle" rowspan="1" colspan="1">t(1;1)(q21;q22)</td><td align="left" valign="middle" rowspan="1" colspan="1">Soft tissue sarcoma</td><td align="left" valign="middle" rowspan="1" colspan="1">LOXO-101</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Doebele <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">CRC</td><td align="left" valign="middle" rowspan="1" colspan="1">Entrectinib</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Sartore-Bianchi <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>NTRK2</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to VCL</td><td align="left" valign="middle" rowspan="1" colspan="1">t(9;10)(q22.1;q22)</td><td align="left" valign="middle" rowspan="1" colspan="1">HGG</td><td align="left" valign="middle" rowspan="1" colspan="1">TRKA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Wu et al. 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to AGBL4</td><td align="left" valign="middle" rowspan="1" colspan="1">t(9;1)(q22.1;p33)</td><td align="left" valign="middle" rowspan="1" colspan="1">HGG</td><td align="left" valign="middle" rowspan="1" colspan="1">TRKA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Wu et al. 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>NTRK3</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to ETV6</td><td align="left" valign="middle" rowspan="1" colspan="1">t(12;15)(p13;q25)</td><td align="left" valign="middle" rowspan="1" colspan="1">Thyroid cancer</td><td align="left" valign="middle" rowspan="1" colspan="1">TRKA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">2-14</td><td align="left" valign="middle" rowspan="1" colspan="1">Ricarte-Filho <italic>et al.</italic> 2013</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">CFS</td><td align="left" valign="middle" rowspan="1" colspan="1">TRKA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Knezevih <italic>et al.</italic> 1998</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">IMT</td><td align="left" valign="middle" rowspan="1" colspan="1">TRKA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Yamamoto <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">GIST</td><td align="left" valign="middle" rowspan="1" colspan="1">TRKA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Brenca <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">MASC</td><td align="left" valign="middle" rowspan="1" colspan="1">TRKA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Skalov&#x000e0; <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">HGG</td><td align="left" valign="middle" rowspan="1" colspan="1">TRKA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Wu et al. 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to BTBD1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(15;15)(p24;q25)</td><td align="left" valign="middle" rowspan="1" colspan="1">HGG</td><td align="left" valign="middle" rowspan="1" colspan="1">TRKA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Wu et al. 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>AKT2</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to BCAM</td><td align="left" valign="middle" rowspan="1" colspan="1">t(19;19)(q13.2;q13.3)</td><td align="left" valign="middle" rowspan="1" colspan="1">HGSC</td><td align="left" valign="middle" rowspan="1" colspan="1">AKT2 inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">10</td><td align="left" valign="middle" rowspan="1" colspan="1">Kannan <italic>et al.</italic> 2015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>PRKACA</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to DNAJB1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(19;19)(p13.1;p13.2)</td><td align="left" valign="middle" rowspan="1" colspan="1">FL-HCC</td><td align="left" valign="middle" rowspan="1" colspan="1">PKA inhibitors</td><td align="left" valign="middle" rowspan="1" colspan="1">100</td><td align="left" valign="middle" rowspan="1" colspan="1">Honeyman <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>PRKD1</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to ARID1A</td><td align="left" valign="middle" rowspan="1" colspan="1">t(14;1)(q12;p36)</td><td align="left" valign="middle" rowspan="1" colspan="1">Salivary gland tumor</td><td align="left" valign="middle" rowspan="1" colspan="1">PRKD1 inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;3</td><td align="left" valign="middle" rowspan="1" colspan="1">Weinreb <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>MET</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to PTPRZ1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(7;7)(q31.2;q31.3)</td><td align="left" valign="middle" rowspan="1" colspan="1">GBM</td><td align="left" valign="middle" rowspan="1" colspan="1">MET inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">15</td><td align="left" valign="middle" rowspan="1" colspan="1">Bao <italic>et al.</italic> 2014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><italic>PIK3CA</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">Fusion to TBL1XR1</td><td align="left" valign="middle" rowspan="1" colspan="1">t(3;3)(q26.3;q26.32)</td><td align="left" valign="middle" rowspan="1" colspan="1">BC</td><td align="left" valign="middle" rowspan="1" colspan="1">PIK3CA inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Stransky et al. 2015</td></tr></tbody></table><table-wrap-foot><p><bold>Abbreviation:</bold> BC: breast cancer, CCA: cholangiocarcinoma, CFS: congenital fibrosarcoma, CRC: colon-rectal cancer, ESCC: esophageal squamous cell carcinoma, FL-HCC: fibrolamellar hepatocellular carcinoma, FLIT: fetal lung interstitial tumor, GBM: glioblastoma, GIST: gastrointestinal stromal tumor, HGG: high grade glioma, HGSC: high-grade serous ovarian cancer, IMT: imflammatory myofibroblatic tumor, MASC: mammary analogue secretory carcinoma of salivary glands, NPC: nasopharyngeal carcinoma, NSCLC: non-small cell lung cancer</p></table-wrap-foot></table-wrap><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Structure and Signaling Transduction Motifs of Tyrosine Kinase Fusions</title><p>The constitutive activation of Tyrosine Kinase Fusion oncoproteins are achieved through multiple mechanisms taking advantage of direct or indirect oligodimerization. Seldom no dimerization are required. Fusion partners can also engage <italic>per se</italic> oncogenic signaling pathways, directly or indirectly modulating Transcription Factors (i.e. NFkB) and their corresponding genes. Kinase activation induces multiple canonical pathways (PI3K/AKT, JAK/STAT, PLC&#x003b3;/PKC and RAS/ERK), which regulate genes controlling transcription and providing pro-tumorigenic signals. Compensatory pathways and regulatory modalities may act in place (i.e. miRNA regulation).</p></caption><graphic xlink:href="oncotarget-07-25064-g001"/></fig><p>Gene fusions typically replace the TK promoter; therefore TKF expression becomes ectopically regulated by the promoter of the partner gene. Partner genes contribute to the oncogenic potential in a number of ways. In most instances, the partner N-terminus region provides dimerization domains, which recruit molecular adaptors and lead to the constitutive trans-phosphorylation and activation of the kinase. TKF partners can also directly activate oncogenic pathways, as observed in the TFG-NTRK1 and TRAF1-ALK fusions, independently activating the NF-kB pathway [<xref rid="R15" ref-type="bibr">15</xref>]. We and others have recently demonstrated that a small subset of systemic (&#x0003c;5%) and cutaneous (~20%) Anaplastic Large Cell Lymphomas (ALCL) bears ROS1 or TYK2 fusions. In such cases, the TKF N-terminus region comprises a transcription factor (NFkB) or a transcriptional repressor (NCOR2) fused to ROS1 and TYK2, respectively [<xref rid="R16" ref-type="bibr">16</xref>]. These TKFs clearly illustrate how the chimera may also influence the transcriptional activity of the partner genes, perturbing transcription promotion or repression. This, in turn, may lead to a widespread derangement of several metabolic and signaling pathways, which ultimately concur to neoplastic transformation [<xref rid="R15" ref-type="bibr">15</xref>, <xref rid="R16" ref-type="bibr">16</xref>]. The N-terminus can also contribute to the neoplastic phenotype by preventing protein degradation through the recruitment of heat shock proteins (Hsp70, Hsp90) [<xref rid="R17" ref-type="bibr">17</xref>]. This may constitute a valid therapeutic target, as observed with Hsp90 inhibitors for the treatment of NPM-ALK ALCL [<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R17" ref-type="bibr">17</xref>] and FLT3-positive leukemias [<xref rid="R18" ref-type="bibr">18</xref>]. Fusion partners can further contribute to neoplastic transformation by directing TKF localization. In T-ALL, for example, NUP214 of the NUP214-ABL orchestrates TKF nuclear pore localization, which is required for neoplastic transformation [<xref rid="R19" ref-type="bibr">19</xref>]. Similarly, the ectopic localization of NPM-ALK and FOP-FGFR1 contributes to oncogenesis by impacting centrosome deregulation and chromosomal instability. Lastly, fusion partners can act as dominant negative mutants. By decreasing the access to wild-type TPM3, TPM3-ALK fusions induce changes in the cytoskeleton organization and confer a higher metastatic capacity [<xref rid="R20" ref-type="bibr">20</xref>].</p></sec><sec id="s3"><title>TKF IN HUMAN CANCERS</title><p>TKFs are found in many human cancers, although at very different frequencies. Among recurrent translocations, hematologic cancers were first shown to carry rearrangements characterized by TKF expression. Subsequent studies demonstrated that <italic>RET</italic> [<xref rid="R21" ref-type="bibr">21</xref>], <italic>TRK</italic> [<xref rid="R22" ref-type="bibr">22</xref>] or <italic>NTRK1</italic> [<xref rid="R23" ref-type="bibr">23</xref>] were frequently translocated in a fraction of thyroid carcinomas, as well as other epithelial and soft tissue neoplasms [<xref rid="R24" ref-type="bibr">24</xref>, <xref rid="R25" ref-type="bibr">25</xref>]. This list has grown steadily to &#x0003e;300 oncogenic TKF [<xref rid="R5" ref-type="bibr">5</xref>] (<ext-link ext-link-type="uri" xlink:href="http://cgap.nci.nih.gov/Chromosomes/Mitelman">http://cgap.nci.nih.gov/Chromosomes/Mitelman</ext-link>) (Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>).</p><sec id="s3_1"><title>Are TKF drivers or passengers in human oncogenesis?</title><p>There is strong evidence that both TK and TKFs play an oncogenic role in human cancers [<xref rid="R26" ref-type="bibr">26</xref>-<xref rid="R28" ref-type="bibr">28</xref>]. Nevertheless, TKF-driven transformation requires multiple genomic defects and the contribution of the host microenvironment to drive oncogenesis. This paradigm is well represented by Chronic Eosinophilic Leukemia (CEL), where the sustained expression of FIP1L1-PDGFRA is necessary (but insufficient) to sustain eosinophils proliferation [<xref rid="R29" ref-type="bibr">29</xref>]. In humans, CEL also requires the overexpression of IL-5 through a single nucleotide polymorphism of <italic>IL5RA</italic>. The same holds true for systemic mastocytosis (SM), in which the constitutive activation of c-KIT alone is insufficient to induce the neoplastic phenotype and requires the stimulation of stem cell factor (SCF) as well [<xref rid="R30" ref-type="bibr">30</xref>].</p><p>This view is somehow challenged by seminal studies on other myeloproliferative neoplasms (MPNs), like CML, which may in fact represent monogenic disorders. The implantation of BCR-ABL (p210) retroviral-transduced marrow precursors into recipient mice can indeed cause rapidly progressing MPNs, which closely resemble human CML [<xref rid="R31" ref-type="bibr">31</xref>]. Of note, this scenario is hardly achievable in mouse models, where the TKF is ectopically expressed by means of more conventional molecular strategies [<xref rid="R32" ref-type="bibr">32</xref>, <xref rid="R33" ref-type="bibr">33</xref>]. Moreover, Foley <italic>et al.</italic> have recently shown that the expression of BCR-ABL alone from the knock-in allele is unable to induce leukemia [<xref rid="R34" ref-type="bibr">34</xref>], suggesting that this TKF is <italic>per se</italic> insufficient to induce a disease fully recapitulating human CML. This latter hypothesis is consistent with the observation of BCR-ABL-positive hematopoietic cells also in healthy individuals [<xref rid="R35" ref-type="bibr">35</xref>], but is challenged by the observation that a fraction of CML patients who have achieved a sustained complete molecular remission (CMR) on imatinib can remain in CMR after drug withdrawal [<xref rid="R36" ref-type="bibr">36</xref>]. This latter observation raises the possibility that BCR-ABL signaling may not be the only driving force in some cases of CML. Of note, the concomitant loss of p14 (ARF) [<xref rid="R37" ref-type="bibr">37</xref>-<xref rid="R39" ref-type="bibr">39</xref>], and the critical role of Bcl-6 [<xref rid="R40" ref-type="bibr">40</xref>], miR-29 [<xref rid="R41" ref-type="bibr">41</xref>], and Raf1 [<xref rid="R42" ref-type="bibr">42</xref>] in CML suggest that the co-occurrence of selective defects and/or the full activation of selective pathways are required to achieve the complete neoplastic phenotype. This is line with the recent observation that IKF1-mutated Ph-positive high-risk ALL, in which IKF1 and Arf alterations synergistically promote the development of an aggressive lymphoid leukemia, can be effectively treated with retinoid receptor agonists which potentiate the activity of dasatinib in mouse and human BCR-ABL1 ALL [<xref rid="R43" ref-type="bibr">43</xref>].</p><p>The evidence that normal T-lymphocytes can undergo neoplastic transformation upon ectopic expression of fusion proteins alone (e.g. NPM-ALK) may further challenge the aforementioned paradigm [<xref rid="R44" ref-type="bibr">44</xref>]. Further studies are however needed to clarify this issue, as TKF transcripts have also been documented in healthy T-cells and in normal hematopoietic cells [<xref rid="R35" ref-type="bibr">35</xref>, <xref rid="R45" ref-type="bibr">45</xref>]. Taken together, these observations indicate that TKFs alone are probably unable to drive T-cell neoplastic transformation completely and require secondary chromosomal abnormalities/TK activating mutations [<xref rid="R46" ref-type="bibr">46</xref>].</p><p>TKF expression levels may also play a role in tumor development. This is the case of ALK-translocated tumors: high NPM-ALK expression is indeed seen in ALCL, while lower EML4-ALK levels characterize NSCLC. These differences are mainly due to different transcriptional activities of the partner genes. Lastly, the regulation of TKF expression may depend on miRNAs/translational regulation and TKF degradation. Overall, these data provide empirical support to the concept of global neutrality, or near-neutrality (i.e. very weak selection of the mutant clone in the early phases of neoplastic transformation) for TKFs [<xref rid="R47" ref-type="bibr">47</xref>].</p></sec><sec id="s3_2"><title>Are TKFs required for the maintenance of a neoplastic phenotype?</title><p>It is generally believed that TKFs contribute to the maintenance of the neoplastic phenotype. This is well exemplified by the therapeutic success of TK inhibitors (TKi) for the treatment of chronic/indolent hematologic disorders (CML and CEL) [<xref rid="R48" ref-type="bibr">48</xref>, <xref rid="R49" ref-type="bibr">49</xref>]. The oncogenic contribution of TKF to tumor maintenance can nevertheless vary according to several variables, including: (i) the properties of each fusion; (ii) the cellular context and the tumor microenvironment; (iii) the disease stage and evolution phase [<xref rid="R28" ref-type="bibr">28</xref>, <xref rid="R49" ref-type="bibr">49</xref>]; (iv) the degree of oncogenic addiction to the TKF (e.g. ROS1-positive NSCLCs show better response to Crizotinib than ALK-positive NSLCLs) [<xref rid="R50" ref-type="bibr">50</xref>]; (v) the presence of concomitant genomic aberrations [<xref rid="R30" ref-type="bibr">30</xref>, <xref rid="R51" ref-type="bibr">51</xref>]. In particular, the occurrence of multiple genetic defects may influence the response to therapy. This is the case of genetically complex disorders (e.g. ALL or end-stage solid cancers), which show a very aggressive clinical behavior and only partial responses to TKi [<xref rid="R52" ref-type="bibr">52</xref>]. The same holds true for some cases of ALK+ ALCL. The majority of ALK+ ALCL patients have a fairly good outcome with conventional chemotherapy treatments. However, rapid and even leukemic progression can occur. These are frequently associated with disrupting events, including <italic>TP53</italic> and <italic>Blimp1</italic> deletions [<xref rid="R53" ref-type="bibr">53</xref>] and <italic>c</italic>-<italic>myc</italic> translocation/amplifications. The acquisition of secondary events may indeed be linked to a more aggressive phenotype and can damper the addiction to ALK signaling [<xref rid="R15" ref-type="bibr">15</xref>]. This mechanism has also been reported in CML in blast crisis [<xref rid="R54" ref-type="bibr">54</xref>] and in ALK-positive NSLCLs resistant to Crizotinib. In the first case, BCR-ABL induces an IGF1 autocrine loop via Hck and Stat5b, in the latter case, the IGF-1R signaling synergizes with (and overcome) ALK by engaging the adaptor protein IRS-1 [<xref rid="R51" ref-type="bibr">51</xref>]. Moreover, restoration of p16 (INKa) or p14 (ARF) into Ph-positive leukemic cells (both CML in blast crisis and ALL) is able to determine cell growth arrest and/or apoptosis suggesting a pathogenic role for these deletions and their co-operating role with BCR-ABL [<xref rid="R39" ref-type="bibr">39</xref>].</p></sec><sec id="s3_3"><title>TKFs in hematopoietic disorders</title><p>Among hematologic malignancies, distinct subsets of acute leukemias, MPNs and non-Hodgkin lymphomas harbor specific TKFs (Table <xref ref-type="table" rid="T1">1</xref>).</p><p>The most frequent TKFs involve <italic>ABL-1</italic> and <italic>PDFGRa/b</italic>, but translocations of <italic>ARG</italic>, <italic>JAK2</italic>, <italic>NTRK3</italic> and <italic>SYK</italic> have been reported, as well. Not all partner genes provide oligodimerization domains, as in the case of the FIP1L1-PDGFRa fusion, which leads to the activation of the kinase moiety by disruption of its juxtamembrane regulatory motif [<xref rid="R55" ref-type="bibr">55</xref>]. Alternatively, the partners do not interact directly, but engage intermediate proteins leading to an indirect dimerization (e.g. CTCCL-ALK, NUP214-ABL, FOP-FGFR1).</p><p>The t(9;22)(q34;q11) translocation juxtaposes the <italic>BCR</italic> and <italic>ABL1</italic> genes in virtually all cases of CML and in a subset of adult/pediatric ALL. The latter may represent a <italic>de novo</italic> disease or, as in many adults, the blastic transformation of CML. Of note, adult and (more frequently) pediatric ALL carry other TKFs, which are associated with a Ph-like phenotype [<xref rid="R9" ref-type="bibr">9</xref>]. The oncogenic properties of such fusions have been demonstrated in a large variety of <italic>in vitro</italic> and <italic>in vivo</italic> systems [<xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R56" ref-type="bibr">56</xref>, <xref rid="R57" ref-type="bibr">57</xref>]. The second most common TKFs involve PDGFR&#x003b1;, PDGFR&#x003b2; and FGFR1. Such TKFs characterize a group of hematological disorders, sharing similar clinico-pathological features, such as peripheral blood eosinophilia, clinical presentation as MPN and/or lymphoid tumors, and, at least for PDGFR&#x003b1; and PDGFR&#x003b2; fusions, good response to Imatinib. For this reason, the 2008 WHO Classification of hematopietic and lymphoid tumors has introduced a separate diagnostic category for such disorders, referred to as &#x0201c;Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFR&#x003b1;, PDGFR&#x003b2; or FGFR1&#x0201d; [<xref rid="R58" ref-type="bibr">58</xref>].</p><p>Among mature T-cell neoplasms, subsets of Peripheral T-cell Lymphomas, not otherwise specified (PTCL, NOS) and Angioimmunoblastic T-cell Lymphomas (AITL) display <italic>SYK</italic> translocations and ITK-SYK fusion proteins [<xref rid="R59" ref-type="bibr">59</xref>-<xref rid="R61" ref-type="bibr">61</xref>]. ALK chimeras have been reported in a subset of ALCL (ALK-positive ALCL) [<xref rid="R59" ref-type="bibr">59</xref>], which are again recognized as a specific entity by the 2008 WHO Classification. Of note, the aberrant expression of ITK-SYK and NPM-ALK fusions in mice can lead to T-cell transformation [<xref rid="R61" ref-type="bibr">61</xref>, <xref rid="R62" ref-type="bibr">62</xref>]. In particular, ITK-SYK mediates lymphomagenesis through the N-terminal phosphatidylinositol 3,4,5-trisphosphate-binding pleckstrin homology (PH) domain of ITK and SLP-76. ALK fusions, on the other hand, require the kinase domain and its flanking regions to activate multiple signaling pathways [<xref rid="R59" ref-type="bibr">59</xref>, <xref rid="R63" ref-type="bibr">63</xref>]. Novel translocations involving <italic>TYK2</italic> and <italic>ROS-1</italic> in CD30-positive cutaneous lymphoproliferative disorders [<xref rid="R64" ref-type="bibr">64</xref>] and systemic ALK-negative ALCL [<xref rid="R16" ref-type="bibr">16</xref>] have been previously described. Interestingly, in addition to <italic>NPM-1</italic>, <italic>NFkB2</italic> and <italic>NCOR2</italic> are partners of these new TKFs and contribute to the neoplastic phenotype [<xref rid="R16" ref-type="bibr">16</xref>]. Finally, precursor T-cell neoplasms (i.e. T-cell acute lymphoblastic lymphoma [T-ALL]) may also harbor TKFs, which usually involve the <italic>ABL</italic> gene. Some of such translocations are also observed in B-ALL (e.g. ABL-NUP214), while others seem to be specific of T-ALL (ABL-EML1) [<xref rid="R65" ref-type="bibr">65</xref>] (Table <xref ref-type="table" rid="T1">1</xref>). Interestingly, several lymphoproliferative disorders also display TK oncogenic mutations, further demonstrating the tumorigenic role of deregulated kinase signaling in hematopoietic disorders [<xref rid="R66" ref-type="bibr">66</xref>, <xref rid="R67" ref-type="bibr">67</xref>].</p><p>TKFs are less frequent in mature non-Hodgkin B-cell neoplasms, with the notable exception of ALK-positive diffuse large B-cell lymphoma, in which the TKFs bear distinct oncogenic and clinico-pathological features [<xref rid="R68" ref-type="bibr">68</xref>] (Table <xref ref-type="table" rid="T1">1</xref>).</p></sec><sec id="s3_4"><title>TKFs in solid tumors</title><p>In solid tumors, aberrant TK activity results from diverse mechanisms, including: (i) point mutations; (ii) gene amplifications; (iii) gene overexpression; and (iv) chromosomal translocations [<xref rid="R51" ref-type="bibr">51</xref>, <xref rid="R69" ref-type="bibr">69</xref>, <xref rid="R70" ref-type="bibr">70</xref>]. Abnormal TK activity can also result from <italic>de novo</italic> transcription initiation (ATI) sites, which lead to the synthesis of truncated intracellular TKDs (e.g. ALK<sup>ATI</sup> in melanoma or ERBB4<sup>ATI</sup> in ALCL) [<xref rid="R71" ref-type="bibr">71</xref>, <xref rid="R72" ref-type="bibr">72</xref>].</p><p>In recent years, a wide array of recurrent translocations has been reported in solid tumors (Table <xref ref-type="table" rid="T2">2</xref>) [<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R28" ref-type="bibr">28</xref>]. In a systematic survey of nearly 7000 samples from the Cancer Genome Atlas, Stransky <italic>et al.</italic> have depicted an extremely variegated translocation landscape in solid tumors [<xref rid="R5" ref-type="bibr">5</xref>], which can display heterogeneous chromosomal translocations, with specific malignancies (such as sarcomas) being characterized by a high percentage of non-recurrent translocations and/or infrequent but recurrent gene fusions.</p><p>To date, fusions involving 14 different TKs have been described in solid tumors (Table <xref ref-type="table" rid="T1">1</xref>). ALK is translocated in several tumors, including lung, colorectal, breast, renal, thyroid carcinomas and soft tissue tumors.</p><p>To date, fusions involving 14 different TKs have been described in solid tumors (Table <xref ref-type="table" rid="T1">1</xref>). ALK is translocated in several tumors, including lung, colorectal, breast, renal, thyroid carcinomas and soft tissue tumors. Fusion partners include <italic>EML4</italic>, <italic>TFG</italic>, <italic>KIF5B</italic>, <italic>KLC1</italic> and <italic>STRN</italic> [<xref rid="R28" ref-type="bibr">28</xref>]. Rare translocations involving <italic>SMEK2</italic> (rectal adenocarcinoma) or <italic>GTF</italic>2IRD1 (thyroid carcinoma) have also been reported.</p><p>Next generation sequencing (NGS) analyses have highlighted new patterns of translocations, defining specific subgroups of common solid tumors (<italic>BRAF</italic> in melanoma; <italic>FGFR1</italic>, <italic>FGFR2</italic>, <italic>FGFR3</italic> in lung cancer; <italic>NTRK</italic> in thyroid cancer), and in clinically unmet patients (<italic>BRAF</italic> and <italic>FGFR1</italic> translocations in pediatric low-grade glioma; <italic>NTRK1</italic> and <italic>NTRK2</italic> in high-grade gliomas, and cholangiocarcinoma, Table <xref ref-type="table" rid="T1">1</xref>). Lastly, MET is involved in chromosomal translocations of secondary glioblastomas and papillary renal carcinomas and <italic>PI3KCA</italic> translocations are observed in breast and prostate carcinomas.</p><p>The transforming activity of TKF in solid cancers has been extensively characterized through pre-clinical models [<xref rid="R73" ref-type="bibr">73</xref>], proving that classical MEK-ERK and PI3K-AKT pathways are critical players in sustaining the transformed phenotype and in mediating resistance to targeted therapies [<xref rid="R74" ref-type="bibr">74</xref>]. TKF dependency thus provides a molecular explanation for the &#x0201c;oncogene addiction&#x0201d; of different TKF-driven tumors [<xref rid="R75" ref-type="bibr">75</xref>].</p><p>Mechanistically, multiple causes of chromosomal translocations have been predicted: (i) exposure to toxic agents (probably the major initiating event); (ii) exposure to ionizing radiation (e.g. in papillary thyroid carcinoma); (iii) oxidative stress and chemotherapeutic agents (e.g. topoisomerase inhibitors).</p></sec></sec><sec id="s4"><title>DISCOVERY AND DETECTION OF TK FUSIONS</title><p>The oncogenic role of TKFs has prompted huge efforts to improve their detection in cancer patients to better guide patient-directed treatment strategies [<xref rid="R76" ref-type="bibr">76</xref>].</p><p>Affinity purification coupled with mass spectrometry (AP-MS) is a powerful tool to characterize aberrant gene products and protein-protein interactions (PPIs). AP-MS has been successfully used to discover novel TKFs in NSCLC (ALK and ROS1) [<xref rid="R77" ref-type="bibr">77</xref>] and rare TKFs in other tumor histotypes [<xref rid="R78" ref-type="bibr">78</xref>]. AP-MS could also define activating mutations linked to TKi-resistant phenotypes [<xref rid="R79" ref-type="bibr">79</xref>]. Furthermore, proteomic patterns distinguish normal from pathological tissues and correctly classify primary/metastatic lesions, allowing tailored treatments and a better stratification of NSCLC [<xref rid="R80" ref-type="bibr">80</xref>].</p><p>The introduction of NGS-based approaches has rapidly enriched the overall knowledge of TKF, giving a better representation of their distribution in human cancers. In hematologic malignancies, NGS studies of Ph-like ALL have detected TKFs in &#x0003e;90% of patients [<xref rid="R8" ref-type="bibr">8</xref>]. Technically, both RNAseq and Whole Exome Sequence (WES) made these achievements possible. In some cases an exon capture specific for TK genes followed by massive parallel sequencing was applied [<xref rid="R81" ref-type="bibr">81</xref>-<xref rid="R84" ref-type="bibr">84</xref>]. Since these analyses can be performed on formalin-fixed paraffin-embedded samples, they can be applied to routine clinical practice. The possibility to test archived material will also allow for the characterization of the clonal evolution of TKF-bearing tumors, with consequent implementation of cancer tailored therapies.</p><sec id="s4_1"><title>Clinical diagnostic tests: tumor fingerprints</title><p>Clinically, TKF in human hematological cancers can be detected by an array of techniques. Genomic/conventional cytogenetics (CG) or FISH are commonly used for the detection of BCR-ALB translocations. Negative samples (&#x0003c;5% of cases) frequently carry variant translocations or cryptic rearrangements, which can occasionally be detected by FISH. Both approaches are also used to monitor drug responses and disease evolution. FISH and RT-PCR have shown higher sensitivity at diagnosis and better MRD detection than CG. In particular, qRT-PCR has become the gold standard for the diagnosis of MRD [<xref rid="R49" ref-type="bibr">49</xref>]. FuseFISH probe-based approaches for the detection of fusion transcripts have also recently emerged [<xref rid="R85" ref-type="bibr">85</xref>], but their usefulness in clinical practice is uncertain.</p><p>Resistance to TKi treatments is currently detected by RT-PCR coupled with DNA Sanger sequencing, but new methods have been developed. Massive parallel sequencing is rapidly replacing the above reported strategies, as it can also identify subclonal populations and characterize tumor clonal heterogeneity [<xref rid="R86" ref-type="bibr">86</xref>]. Analogous approaches have now been extended to the detection of actionable mutations, copy number variations, and gene rearrangement in clinical cancer specimens.</p><p>In solid tumors, TKFs are clinically identified by several techniques, some of which are performed as companion tests to select the best TKi agent. In 2013, the USA and China's FDA approved FISH- and IHC-based diagnostic tests to identify <italic>ALK</italic> fusions or ALK protein expression in NSCLC. Similar strategies were proposed to assess <italic>ROS1</italic> and <italic>RET</italic> fusions [<xref rid="R87" ref-type="bibr">87</xref>]. Alternatively, a NGS-based detection kit for <italic>RET</italic>-rearrangements has been used to enroll patients in NSLCL clinical trials (Eisai sponsored trial; NCT01829217). It is conceivable that screening approaches to detect simultaneously multiple fusions will be implemented in the clinical arena [<xref rid="R88" ref-type="bibr">88</xref>].</p><p>Since different TKFs can be present in distinct cancer subsets, multi-targeted platforms have emerged as powerful tools to screen diagnostic samples. As multi-gene screening methods are entering into routine diagnostic procedures, new technical and therapeutic questions need to be addressed. Indeed, the greater efficacy of TKi compared to conventional treatments needs to be established for na&#x000ef;ve patients carrying targetable fusions. Similarly, patients treated with multiple rounds of chemotherapeutic regimens need to be evaluated for the compliance to selective TKi, as limited data are available to justify their usage.</p></sec></sec><sec id="s5"><title>TUMOR-ASSOCIATED TK TRANSLOCATIONS: CURRENT THERAPEUTIC STRATEGIES</title><p>The discovery of recurrent tumor-associated TK translocations has brought new strategies for the treatment of hematologic and non-hematologic tumors. In the last decades, TKi have revolutionized the treatment of CML, Ph-positive B-ALL [<xref rid="R89" ref-type="bibr">89</xref>] and NSCLC carrying <italic>ALK</italic> or <italic>ROS-1</italic> gene rearrangements [<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R90" ref-type="bibr">90</xref>].</p><sec id="s5_1"><title>TKi-based therapies for the treatment of hematological tumors</title><p><italic>BCR-ABL1</italic> gene rearrangements are reported in all cases of CML and in about 30% of adult B-ALL. The fusion gene usually results from the t(9;22)(q34;q11.2) translocation, but 5-10% of cases bear variants and/or cryptic translocations [<xref rid="R2" ref-type="bibr">2</xref>]. BCR-ABL1 oncogenic properties are due to the constitutive activation of ABL1 TK [<xref rid="R91" ref-type="bibr">91</xref>, <xref rid="R92" ref-type="bibr">92</xref>] and the loss of ABL-1 N-terminus regulatory domain.</p><p>Clinically, Imatinib has revolutionized the prognosis and outcome of CML, converting a highly lethal hematological neoplasm to a chronic and curable disease [<xref rid="R49" ref-type="bibr">49</xref>]. Complete cytogenetic responses (CCyR) are indeed reported in 87% of Imatinib-treated patients, with a progression-free survival (PFS) of 93% [<xref rid="R93" ref-type="bibr">93</xref>]. After 2 years of sustained CCyR, the life expectancy for CML patients is comparable to that of the general population [<xref rid="R94" ref-type="bibr">94</xref>]. Despite these results, several studies pinpointed a subset of cases with primary/secondary resistance to Imatinib, which can be overcome by new generation TKi (i.e. Nilotinib, Dasatinib and Bosutinib) with improved clinical efficacy [<xref rid="R95" ref-type="bibr">95</xref>]. These lines of evidence led the European Leukemia Net to recommend Imatinib, Nilotinib and/or Dasatinib as first line drugs for the treatment of CML. More aggressive therapeutic approaches (e.g. hematopoietic stem cell transplant) are considered only in very selected cases (e.g. refractory/relapsing cases unresponsive to TKi or accelerated/blast phase CML) [<xref rid="R49" ref-type="bibr">49</xref>].</p><p>In CML patients, resistance to TKi can result from two major mechanisms: (i) occurrence of TKi-resistant BCR-ABL1 mutations; (ii) enhancement of BCR-ABL1-independent pro-survival pathways. BCR-ABL1-dependent resistance has been overcome by third generation TKi that also target the most common ABL1 mutations (e.g. BCR-ABL1<sup>T315I</sup>). The most promising therapeutic agents are the conventional TKi, Ponatinib, and the BCR-ABL1 switch control inhibitor, DCC-2036 [<xref rid="R96" ref-type="bibr">96</xref>]. Notably, good results with Ponatinib have been obtained even in accelerated and blast phase CML [<xref rid="R97" ref-type="bibr">97</xref>], while the distinct action of DCC-2036 may overcome pre-existing mutations, including T315I [<xref rid="R96" ref-type="bibr">96</xref>]. Pemovska <italic>et al.</italic> have recently re-proposed the utility of Axitinib, an anti-VEGFR molecule approved for renal cell carcinoma, to counteract the resistance phenotype of T315I gatekeeper CML. Indeed, Axitinib tightly binds the T315I mutated kinase and inhibits leukemic cell growth, showing a better toxicity profile than other new-generation drugs, such as Ponatinib [<xref rid="R98" ref-type="bibr">98</xref>].</p><p>BCR-ABL1-independent resistance is mainly due to the activation of alternative signaling pathways promoting neoplastic cell survival [<xref rid="R99" ref-type="bibr">99</xref>]. Such pathways can be either extrinsic (i.e. activated by the marrow microenvironment) or intrinsic (i.e. due to microenvironment-independent mechanisms). Both intrinsic and extrinsic pathways lead to the activation of STAT3, through its phosphorylation at Tyr-705 [<xref rid="R100" ref-type="bibr">100</xref>]. Combined inhibition of STAT via BP-5-087, a potent and selective STAT3 SH2 domain inhibitor and BCR-ABL1 leads to synthetic lethality in resistant CML and constitutes a very promising therapeutic approach for refractory/relapsing CML [<xref rid="R100" ref-type="bibr">100</xref>]. Another therapeutic opportunity is represented by glitazones, anti-diabetic drugs that down-regulate STAT5 expression by inhibiting the peroxisome proliferator-activated receptor-&#x003b3; (PPAR&#x003b3;). Recent data show that their use may lead to the complete eradication of leukemic stem pools, thus greatly improving the survival of CML patients in sustained CMR [<xref rid="R101" ref-type="bibr">101</xref>].</p><p>Unlike what has been observed in CML, the use of single-agent TKi in Ph-positive ALL has not produced sustained clinical responses. This is probably due to the rapid development of TK mutations, which are reported in &#x0003e;80% of adult Ph-positive ALLs at relapse [<xref rid="R102" ref-type="bibr">102</xref>]. Ph-positive ALL and CML also greatly differ in terms of genomic backgrounds, which may influence the response to TKi. For instance, INK4-ARF deletions, which often occur in acute Ph-positive ALL with aggressive clinical course, facilitate the emergence of BCR-ABL drug-resistant clones. This molecular event is not observed in indolent CML or in CML in blast crisis [<xref rid="R103" ref-type="bibr">103</xref>].</p><p>These data provide the rationale for the use of multi-modal regimens for the treatment of Ph-positive ALL, based on a combination of intensive chemotherapy and TKi. Very encouraging results have been first obtained in pediatric trials (COG, EsPhALL and SHOP-2005 trials) [<xref rid="R104" ref-type="bibr">104</xref>, <xref rid="R105" ref-type="bibr">105</xref>] and, more recently, in adult patients [<xref rid="R106" ref-type="bibr">106</xref>]. In particular, a recent Phase II trial on Imatinib mesylate <italic>plus</italic> HyperCVAD (Cyclophosphamide, Vincristine, Doxorubicine, Dexamethasone) has reported complete clinical remission in 93% of adults with active Ph-positive ALL, with a 5-year overall survival (OS) of 43%. Notably, allogeneic stem cell transplant (ASCT) after Imatinib and HyperCVAD improved median OS only in patients with residual molecular disease. The role of Dasatinib and Nilotinib for the treatment of pediatric and adult Ph-positive ALL is still under evaluation, but preliminary results indicate their safety and efficacy when used with high dose chemotherapy and/or ASCT [<xref rid="R107" ref-type="bibr">107</xref>]. Encouraging data have also been obtained with Dasatinib and corticosteroid, which proves the potential efficacy of chemo-free protocols [<xref rid="R108" ref-type="bibr">108</xref>]. Finally, the association of TKi and bispecific T-cell engaging antibodies (BiTE) or chimeric antigen receptors T-cells (CARTs) represents a promising strategy for the treatment of Ph-positive ALL [<xref rid="R109" ref-type="bibr">109</xref>].</p></sec><sec id="s5_2"><title>TKI-based therapies for the treatment of solid tumors</title><p>The introduction of TKi for the treatment of ALK-, ROS1- and RET-translocated NSCLC [<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R110" ref-type="bibr">110</xref>, <xref rid="R111" ref-type="bibr">111</xref>] has led to an astonishing improvement of patients' outcome and survival. More recently, fusions involving <italic>NTRK1</italic> and <italic>FGFR1/2/3</italic> have been reported (Table <xref ref-type="table" rid="T1">1</xref>), thus enlarging the spectrum of promising therapies for NSCLC (i.e. Crizotinib, Ceritinib, Alecitinib for ALK-positive NSCLC; Crizotinib for ROS1-positive NSCLC; Cabozantinib and Vandetanib for RET-positive NSCLC).</p><p>Crizotinib represents the paradigm of efficient translation of molecular knowledge to the bedside. Initially developed as a c-Met inhibitor, Crizotinib showed clinical activity on advanced ALK-positive NSCLC in both the PROFILE 1001 (phase I) and PROFILE 1014 (phase III) clinical trials. Of note, in such tumors, Crizotinib displayed even greater efficacy than standard chemotherapy [<xref rid="R112" ref-type="bibr">112</xref>]. Similar results have been observed in ROS1- or RET-positive NSCLCs, with good responses to Crizotinib in ROS1-positive cases [<xref rid="R14" ref-type="bibr">14</xref>] and to Cabozantinib in Crizotinib-refractory cells [<xref rid="R113" ref-type="bibr">113</xref>]. The application of TKi has recently expanded to RET-mutated medullary thyroid carcinoma, RET-translocated NSCLC and other solid tumors (NCT02183870, NCT0194502, NCT01823068, NCT01639508). More recently, inhibitors with broad spectrum of activities were tested (RXDX-101), providing novel strategies to target different molecular defects (NTRK1/2/3, ROS1 and ALK translocation) shared by wide range of solid tumors (NCT02568267, NCT02097810).</p><p>Despite these outstanding results, TKi often lose their efficacy due to the development of treatment-related resistance [<xref rid="R114" ref-type="bibr">114</xref>]. Much like hematologic neoplasms, primary and secondary mechanisms determine resistance to TKi in solid tumors. Primary resistance is linked to the tridimensional structures of the protein that confer TKi-resistance [<xref rid="R115" ref-type="bibr">115</xref>], whereas secondary resistance mainly consists of gene mutations, bypass mechanisms, and/or gene amplifications overcoming the effect of TKi at therapeutic levels.</p><p>As for target mutations, different genetic alterations associated with resistance have been described for ALK-positive NSCLC: i) L1169M within the &#x0201c;gatekeeper&#x0201d; domain (the most frequent); ii) L1152R, associated with EGFR signaling activation; iii) G1202R and S1206Y within the ATP-binding pocket, leading to a decreased Crizotinib affinity [<xref rid="R116" ref-type="bibr">116</xref>]. The most frequently reported bypass mechanisms associated with secondary resistance to ALK inhibition are: i) EGFR/KRAS mutations [<xref rid="R117" ref-type="bibr">117</xref>] and Tyrosine Kinase Receptor (ERBB, c-MET, etc.) activation triggered by paracrine stimuli [<xref rid="R118" ref-type="bibr">118</xref>, <xref rid="R119" ref-type="bibr">119</xref>]; ii) c-KIT amplification, requiring SCF [<xref rid="R120" ref-type="bibr">120</xref>], IGF-1R up-regulation [<xref rid="R51" ref-type="bibr">51</xref>] and recruitment of P2Y receptors [<xref rid="R121" ref-type="bibr">121</xref>]. Other resistance mechanisms include impaired drug influx (OCT-1), increased drug efflux (MDR1), or microenvironment-mediated resistance [<xref rid="R122" ref-type="bibr">122</xref>].</p><p>Different strategies have been proposed to overcome TKi acquired resistance, including the development of next-generation drugs, such as the ALK-inhibitors LDK378-Ceritinib and AP26113-Brigatinib (for ALK-positive NSCLC resistant to Crizotinib), Lecitinib (for ALK-positive NSCLC carrying the L1169M mutation) and PF06463922 (a dual ALK/ROS1 inhibitor with a good CNS penetration profile) [<xref rid="R123" ref-type="bibr">123</xref>]. Additionally, Hsp-90 inhibitors (AUY922-Ganetespib) are currently under evaluation in phase I/II clinical trials. Other emerging strategies include the administration of combined therapies to by-pass the &#x0201c;addiction&#x0201d; to single TKFs (e.g., combined inhibition of HER family [Dacomitinib], c-KIT [Dasatinib], src [Saracatinib], MEK [AZD6244], and IGF-1R [Linsitinib]). The re-timing of drug administration should also be considered, as recently demonstrated by the case of a Crizotinib-resistant ALK-positive NSCLC, displaying good response to this TKi after a withdrawal period [<xref rid="R124" ref-type="bibr">124</xref>]. Similar results have been obtained in an EGFR-mutated NSCLC, which regained sensitivity to EGFR-inhibitors upon therapy discontinuation [<xref rid="R125" ref-type="bibr">125</xref>]. Lastly, immunotherapeutic strategies (i.e. vaccination against over-expressed oncogenic antigens) may represent an effective approach for solid tumors, as recently reported in ALK-positive disorders [<xref rid="R59" ref-type="bibr">59</xref>, <xref rid="R126" ref-type="bibr">126</xref>].</p><p>A final major roadblock concerning TKi is the poor response of central nervous system (CNS) metastases to therapy. This drawback may be overcome by different strategies: (i) combined therapies with drugs favoring TKi CNS accumulation, as recently attempted through the co-administration of Vandetanib and Everolimus (an immunosuppressive drug also modulating the P-glycoprotein efflux activity) [<xref rid="R127" ref-type="bibr">127</xref>]; and (ii) usage of single compound with higher brain penetrance, such as Ceritinib compared to Crizotinib.</p></sec></sec><sec id="s6"><title>FUTURE PERSPECTIVES</title><p>Despite TKi have dramatically changed the clinical management of numerous cancers, many questions have still to be answered. One of the major problems concerning TKi is the high frequency of primary refractoriness/tumor relapses [<xref rid="R128" ref-type="bibr">128</xref>] (Figure <xref ref-type="fig" rid="F2">2</xref>). Possible solutions for this limitation are: (i) the development of more potent drugs with limited side effects; (ii) the co-administration of TKi and chemotherapeutic agents [<xref rid="R129" ref-type="bibr">129</xref>], immune-based protocols [<xref rid="R130" ref-type="bibr">130</xref>] and/or bone marrow transplant [<xref rid="R131" ref-type="bibr">131</xref>]; and (iii) further research on treatment timing and dosage.</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Mechanisms of Intrinsic and/or Acquired Resistances to Tyrosine Kinase Exposure</title><p>Multiple mechanisms are associated with the emergence of drug resistance. These include: development of secondary mutations in the Kinase Domain (KD) at gatekeeper sites; copy number gains; activation of alternative oncogenic pathways via somatic mutations (i.e. RAS), and compensatory &#x0201c;by-pass&#x0201d; routes by Receptor Tyrosine Kinases signaling (i.e. EGFR, HER-2, HER-3, c-MET). Alternatively, resistance may also be due to either paracrine external signals through the tumor microenvironment, or via autocrine loops. The major drug categories and their therapeutic modalities are indicated.</p></caption><graphic xlink:href="oncotarget-07-25064-g002"/></fig><p>Of note, a growing number of protocols combining chemotherapy and TKi are currently being tested in both TKF-induced hematological and solid tumors [<xref rid="R107" ref-type="bibr">107</xref>, <xref rid="R132" ref-type="bibr">132</xref>] [<xref rid="R133" ref-type="bibr">133</xref>], and several trials are evaluating the efficacy of new TKi either alone or in combination with more conventional therapies (NCT02269085; NCT02427620; NCT02315768; NCT01606878; NCT02134912; NCT02511184). Preclinical studies have also demonstrated a substantial advantage of combining classical chemotherapy with TKi: Das and colleagues showed a synergistic effect of Crizotinib and Temozolomide in FIG-ROS1-positive glioblastoma patient-derived cells, paving a route to improve clinical outcome [<xref rid="R134" ref-type="bibr">134</xref>]. Similarly, Appelmann and colleagues evaluated the possibility of combining Dasatinib, Ruxolitinib and Dexamethasone to prolong remission and avoid major toxicities in a mouse model of Ph-positive ALL [<xref rid="R135" ref-type="bibr">135</xref>].</p><p>One of the most challenging issues on the combined use of TKi and chemotherapeutics concerns the optimal doses and schedules to use. Toward this end, mathematical models might improve the clinical success, limiting unacceptable side effects and TKi/conventional therapy-resistance [<xref rid="R136" ref-type="bibr">136</xref>]. This approach also needs dedicated trials, the cooperative agreement of pharmaceutical companies and new regulations on intellectual and commercial issues. Moreover, we need to develop biological and mathematical models to predict cancer evolution, capable of predicting cancer evolutionary trajectories based on pre-treatment diversity. Lastly, we foresee that these predictions need to be adjusted in each individual patient by integrating longitudinally acquired molecular readouts representative of the global cancer landscape (i.e. comprehensive genomic data [WES] of multiple sites, liquid biopsies, etc.).</p><p>Other questions regarding TKi concern the risks and benefits of second/third generation drugs. Thus, the use of first generation compounds remain a valuable option in many settings, including highly targeted diseases and the management of third world populations. The increasing health costs, the uncontrolled fee schedules in many industrialized countries, the increasing co-payer costs and the accessibility of generic TKi represent very tangible issues which may be solved only via international based supports and regulations. Finally, the need of cutting health system costs poses unprecedented challenges to molecular medicine programs. In fact, the success of such therapies depends on the characterization of individual cancers (both primary and recurrent/metastatic lesions). These analyses have to be performed by a pool of medical centers following certified programs, with consequent huge health costs.</p><p>These practical problems are paralleled by a series of scientific and methodological challenges. Although the genomic characterization of each cancer has originally prompted the use of selective compounds, it is now clear that this approach may not be sufficient. Indeed, favorable responses to selective drugs are not strictly linked to defined genetic defects. Thus, functional tests (e.g. comprehensive phosphorylation maps) should be performed together with genomic analyses. As an alternative, <italic>in vitro</italic> preclinical tests on patient-derived cell lines or PDTX may be introduced (Figure <xref ref-type="fig" rid="F3">3</xref>).</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Comprehensive Management of Tyrosine Kinase-driven Cancers</title><p>Molecular and functional characterization of human cancers in combination with drug screening tests on primary patient tumor samples is expected to drive precise target therapies. It is anticipated that tumor samples will be used to generated 2D/3D and well as PDTX models. <italic>In vitro</italic> models from primary samples or from PDTX will serve to screen large libraries of compounds, whose efficacy will be established using a battery of biological and molecular readouts. The data emerging from these high throughput screenings will be pivotal to test selected molecules in preclinical PDTX-based trials. Extensive molecular and functional readouts will then be obtained from both tumors and host compartments (i.e. plasma/liquid biopsy) to create a detailed profile of <italic>in vivo</italic> classifiers and biomarkers. These will ultimately serve as surrogates to predict and define response to specific therapies in cancer patients. The development of tumor biorepositories of primary and metastatic lesions, cell lines and PDTX from primary human cancers is predicted to lead to the recognition and understanding of new oncogenic events. It is anticipated that effective targeted therapies will improve clinical responses and ultimately will lead to lower health care costs.</p></caption><graphic xlink:href="oncotarget-07-25064-g003"/></fig><p>Of note, <italic>in vitro</italic> tests with patient-derived tissue samples may allow personalized pharmacologic interventions without the limits related to the use of immortalized cell lines or other tumor models. Patient-derived cancer models are indeed pivotal for drug discovery, for the characterization of cancer biology and for the assessment of personalized therapies [<xref rid="R137" ref-type="bibr">137</xref>-<xref rid="R139" ref-type="bibr">139</xref>]. Several cancer PDTX models have been developed, but only handful of them carries TKFs [<xref rid="R15" ref-type="bibr">15</xref>, <xref rid="R140" ref-type="bibr">140</xref>-<xref rid="R142" ref-type="bibr">142</xref>]; thus, a more systematic effort in generating &#x0201c;ad hoc&#x0201d; models is highly recommended.</p><p>We anticipate that <italic>in vitro</italic> primary cell lines will allow for the rapid testing of drug libraries, with subsequent validation in more complex models (e.g. PDTX). It is also desirable that new clinical trials will include parallel co-clinical mouse PDTX-trials, which will establish the efficacy of such models. The molecular stratification of these models will finally provide new cancer classifiers with possible diagnostic/prognostic implications (Figure <xref ref-type="fig" rid="F3">3</xref>).</p><p>The considerable therapeutic progress against TKF-driven tumors may also prove beneficial for the treatment of those translocation-negative neoplasms, which nonetheless carry defects of TKF-related signaling pathways. As previously highlighted, TKFs indeed represent only one of the several mechanisms leading to TK dysfunction, and other TK impairments (i.e. gene mutations/amplifications or non-fusion rearrangements) lead to phenotypes closely resembling those of TKF-driven neoplasms. This is, for instance, the case of subsets of ALK-negative ALCL, carrying JAK1 and STAT3 activating mutations, which induce transcriptional signatures akin to those of ALK-positive ALCL [<xref rid="R16" ref-type="bibr">16</xref>]. Moreover, it is now recognized that activating mutations can synergize with TFKs and lead to full neoplastic transformation [<xref rid="R8" ref-type="bibr">8</xref>]. This molecular evidence constitutes the rationale for the administration of TKi compounds in specific subsets of both TKF-negative and TFK-positive tumors. Further studies and clinical trials will help clarify this captivating opportunity.</p><p>In conclusion, it is desirable that the academic community promotes dedicated programs on TKi and TKF-bearing cancers, also encouraging the support of pharmaceutical companies and the distribution of compounds under compassionate use. This approach, together with the creation of open-access clinical databases, will greatly contribute to the understanding of cancer-related TKFs and to a better management of (TKF-positive and TKF-negative) cancer patients.</p></sec></body><back><ack><p>GI is supported by Italian Association for Cancer Research (AIRC) (5&#x000d7;1000 No. 10007); ImmOnc (BIO F.E.S.R. 2007/13, Asse 1 &#x02018;Ricerca e innovazione' della LR 34/2004) the Oncology Program of Compagnia di San Paolo, Torino and Ricerca Finalizzata, Ministero della Salute.</p></ack><fn-group><fn fn-type="con"><p><bold>Authors' contributors</bold></p><p>FT, MP, PK, BR and GI researched and reviewed the existing literature and editedwrote the manuscript.</p></fn><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTERESTS</bold></p><p>We declare no competing interests.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowell</surname><given-names>PC</given-names></name></person-group><article-title>A minute chromosome in human chronic granulocitic leukemia</article-title><source>Science</source><year>1960</year><volume>132</volume><fpage>1497</fpage></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowley</surname><given-names>JD</given-names></name></person-group><article-title>Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining</article-title><source>Nature</source><year>1973</year><volume>243</volume><issue>5405</issue><fpage>290</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">4126434</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heisterkamp</surname><given-names>N</given-names></name><name><surname>Stam</surname><given-names>K</given-names></name><name><surname>Groffen</surname><given-names>J</given-names></name><name><surname>de Klein</surname><given-names>A</given-names></name><name><surname>Grosveld</surname><given-names>G</given-names></name></person-group><article-title>Structural organization of the bcr gene and its role in the Ph' translocation</article-title><source>Nature</source><year>1985</year><volume>315</volume><issue>6022</issue><fpage>758</fpage><lpage>761</lpage><pub-id pub-id-type="pmid">2989703</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heisterkamp</surname><given-names>N</given-names></name><name><surname>Stephenson</surname><given-names>JR</given-names></name><name><surname>Groffen</surname><given-names>J</given-names></name><name><surname>Hansen</surname><given-names>PF</given-names></name><name><surname>de Klein</surname><given-names>A</given-names></name><name><surname>Bartram</surname><given-names>CR</given-names></name><name><surname>Grosveld</surname><given-names>G</given-names></name></person-group><article-title>Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia</article-title><source>Nature</source><year>1983</year><volume>306</volume><issue>5940</issue><fpage>239</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">6316147</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Schalm</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>JL</given-names></name><name><surname>Lengauer</surname><given-names>C</given-names></name></person-group><article-title>The landscape of kinase fusions in cancer</article-title><source>Nat Commun</source><year>2014</year><volume>5</volume><fpage>4846</fpage><pub-id pub-id-type="pmid">25204415</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullighan</surname><given-names>CG</given-names></name><name><surname>Collins-Underwood</surname><given-names>JR</given-names></name><name><surname>Phillips</surname><given-names>LA</given-names></name><name><surname>Loudin</surname><given-names>MG</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Coustan-Smith</surname><given-names>E</given-names></name><name><surname>Harvey</surname><given-names>RC</given-names></name><name><surname>Willman</surname><given-names>CL</given-names></name><name><surname>Mikhail</surname><given-names>FM</given-names></name><name><surname>Meyer</surname><given-names>J</given-names></name><name><surname>Carroll</surname><given-names>AJ</given-names></name><name><surname>Williams</surname><given-names>RT</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Heerema</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia</article-title><source>Nature genetics</source><year>2009</year><volume>41</volume><issue>11</issue><fpage>1243</fpage><lpage>1246</lpage><pub-id pub-id-type="pmid">19838194</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hantschel</surname><given-names>O</given-names></name></person-group><article-title>Structure, regulation, signaling, and targeting of abl kinases in cancer</article-title><source>Genes &#x00026; cancer</source><year>2012</year><volume>3</volume><issue>5-6</issue><fpage>436</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1177/1947601912458584</pub-id><pub-id pub-id-type="pmid">23226581</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>KG</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Payne-Turner</surname><given-names>D</given-names></name><name><surname>Harvey</surname><given-names>RC</given-names></name><name><surname>Yang</surname><given-names>YL</given-names></name><name><surname>Pei</surname><given-names>D</given-names></name><name><surname>McCastlain</surname><given-names>K</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Song</surname><given-names>G</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Becksfort</surname><given-names>J</given-names></name><name><surname>Rusch</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>SC</given-names></name><name><surname>Easton</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><etal/></person-group><article-title>Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><issue>11</issue><fpage>1005</fpage><lpage>1015</lpage><pub-id pub-id-type="pmid">25207766</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>KG</given-names></name><name><surname>Morin</surname><given-names>RD</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Hirst</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>SC</given-names></name><name><surname>Payne-Turner</surname><given-names>D</given-names></name><name><surname>Churchman</surname><given-names>ML</given-names></name><name><surname>Harvey</surname><given-names>RC</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Kasap</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>C</given-names></name><name><surname>Becksfort</surname><given-names>J</given-names></name><name><surname>Finney</surname><given-names>RP</given-names></name><name><surname>Teachey</surname><given-names>DT</given-names></name><etal/></person-group><article-title>Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia</article-title><source>Cancer Cell</source><year>2012</year><volume>22</volume><issue>2</issue><fpage>153</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">22897847</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valent</surname><given-names>P</given-names></name></person-group><article-title>Targeting the JAK2-STAT5 pathway in CML</article-title><source>Blood</source><year>2014</year><volume>124</volume><issue>9</issue><fpage>1386</fpage><lpage>1388</lpage><pub-id pub-id-type="pmid">25170113</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medves</surname><given-names>S</given-names></name><name><surname>Demoulin</surname><given-names>JB</given-names></name></person-group><article-title>Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies</article-title><source>J Cell Mol Med</source><year>2012</year><volume>16</volume><issue>2</issue><fpage>237</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">21854543</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Tanizaki</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Aref</surname><given-names>AR</given-names></name><name><surname>Rusan</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>SJ</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ercan</surname><given-names>D</given-names></name><name><surname>Liao</surname><given-names>RG</given-names></name><name><surname>Capelletti</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Hur</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Sim</surname><given-names>T</given-names></name><name><surname>Gaudet</surname><given-names>S</given-names></name><etal/></person-group><article-title>Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors</article-title><source>Proc Natl Acad Sci U S A</source><year>2014</year><volume>111</volume><issue>45</issue><fpage>E4869</fpage><lpage>4877</lpage><pub-id pub-id-type="pmid">25349422</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowan-Jacob</surname><given-names>SW</given-names></name><name><surname>Mobitz</surname><given-names>H</given-names></name><name><surname>Fabbro</surname><given-names>D</given-names></name></person-group><article-title>Structural biology contributions to tyrosine kinase drug discovery</article-title><source>Curr Opin Cell Biol</source><year>2009</year><volume>21</volume><issue>2</issue><fpage>280</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">19208462</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>AT</given-names></name><name><surname>Engelman</surname><given-names>JA</given-names></name></person-group><article-title>Ceritinib in ALK-rearranged non-small-cell lung cancer</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><issue>26</issue><fpage>2537</fpage><lpage>2539</lpage><pub-id pub-id-type="pmid">24963575</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abate</surname><given-names>F</given-names></name><name><surname>Todaro</surname><given-names>M</given-names></name><name><surname>van der Krogt</surname><given-names>JA</given-names></name><name><surname>Boi</surname><given-names>M</given-names></name><name><surname>Landra</surname><given-names>I</given-names></name><name><surname>Machiorlatti</surname><given-names>R</given-names></name><name><surname>Tabbo</surname><given-names>F</given-names></name><name><surname>Messana</surname><given-names>K</given-names></name><name><surname>Abele</surname><given-names>C</given-names></name><name><surname>Barreca</surname><given-names>A</given-names></name><name><surname>Novero</surname><given-names>D</given-names></name><name><surname>Gaudiano</surname><given-names>M</given-names></name><name><surname>Aliberti</surname><given-names>S</given-names></name><name><surname>Di Giacomo</surname><given-names>F</given-names></name><name><surname>Tousseyn</surname><given-names>T</given-names></name><name><surname>Lasorsa</surname><given-names>E</given-names></name><etal/></person-group><article-title>A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation</article-title><source>Leukemia</source><year>2015</year><volume>29</volume><issue>6</issue><fpage>1390</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">25533804</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crescenzo</surname><given-names>R</given-names></name><name><surname>Abate</surname><given-names>F</given-names></name><name><surname>Lasorsa</surname><given-names>E</given-names></name><name><surname>Tabbo</surname><given-names>F</given-names></name><name><surname>Gaudiano</surname><given-names>M</given-names></name><name><surname>Chiesa</surname><given-names>N</given-names></name><name><surname>Di Giacomo</surname><given-names>F</given-names></name><name><surname>Spaccarotella</surname><given-names>E</given-names></name><name><surname>Barbarossa</surname><given-names>L</given-names></name><name><surname>Ercole</surname><given-names>E</given-names></name><name><surname>Todaro</surname><given-names>M</given-names></name><name><surname>Boi</surname><given-names>M</given-names></name><name><surname>Acquaviva</surname><given-names>A</given-names></name><name><surname>Ficarra</surname><given-names>E</given-names></name><name><surname>Novero</surname><given-names>D</given-names></name><name><surname>Rinaldi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma</article-title><source>Cancer Cell</source><year>2015</year><volume>27</volume><issue>4</issue><fpage>516</fpage><lpage>532</lpage><pub-id pub-id-type="pmid">25873174</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonvini</surname><given-names>P</given-names></name><name><surname>Gastaldi</surname><given-names>T</given-names></name><name><surname>Falini</surname><given-names>B</given-names></name><name><surname>Rosolen</surname><given-names>A</given-names></name></person-group><article-title>Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><issue>5</issue><fpage>1559</fpage><lpage>1566</lpage><pub-id pub-id-type="pmid">11888936</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Q</given-names></name><name><surname>Nishiuchi</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Kumar</surname><given-names>AR</given-names></name><name><surname>Hudson</surname><given-names>WA</given-names></name><name><surname>Kersey</surname><given-names>JH</given-names></name></person-group><article-title>FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases</article-title><source>Clinical cancer research</source><year>2003</year><volume>9</volume><issue>12</issue><fpage>4483</fpage><lpage>4493</lpage><pub-id pub-id-type="pmid">14555522</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Keersmaecker</surname><given-names>K</given-names></name><name><surname>Rocnik</surname><given-names>JL</given-names></name><name><surname>Bernad</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>BH</given-names></name><name><surname>Leeman</surname><given-names>D</given-names></name><name><surname>Gielen</surname><given-names>O</given-names></name><name><surname>Verachtert</surname><given-names>H</given-names></name><name><surname>Folens</surname><given-names>C</given-names></name><name><surname>Munck</surname><given-names>S</given-names></name><name><surname>Marynen</surname><given-names>P</given-names></name><name><surname>Fornerod</surname><given-names>M</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name><name><surname>Cools</surname><given-names>J</given-names></name></person-group><article-title>Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore</article-title><source>Mol Cell</source><year>2008</year><volume>31</volume><issue>1</issue><fpage>134</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">18614052</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>F</given-names></name><name><surname>Lamant</surname><given-names>L</given-names></name><name><surname>Hieblot</surname><given-names>C</given-names></name><name><surname>Delsol</surname><given-names>G</given-names></name><name><surname>Touriol</surname><given-names>C</given-names></name></person-group><article-title>TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins</article-title><source>Eur J Cancer</source><year>2007</year><volume>43</volume><issue>4</issue><fpage>640</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">17276053</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grieco</surname><given-names>M</given-names></name><name><surname>Santoro</surname><given-names>M</given-names></name><name><surname>Berlingieri</surname><given-names>MT</given-names></name><name><surname>Melillo</surname><given-names>RM</given-names></name><name><surname>Donghi</surname><given-names>R</given-names></name><name><surname>Bongarzone</surname><given-names>I</given-names></name><name><surname>Pierotti</surname><given-names>MA</given-names></name><name><surname>Della Porta</surname><given-names>G</given-names></name><name><surname>Fusco</surname><given-names>A</given-names></name><name><surname>Vecchio</surname><given-names>G</given-names></name></person-group><article-title>PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected <italic>in vivo</italic> in human thyroid papillary carcinomas</article-title><source>Cell</source><year>1990</year><volume>60</volume><issue>4</issue><fpage>557</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">2406025</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greco</surname><given-names>A</given-names></name><name><surname>Pierotti</surname><given-names>MA</given-names></name><name><surname>Bongarzone</surname><given-names>I</given-names></name><name><surname>Pagliardini</surname><given-names>S</given-names></name><name><surname>Lanzi</surname><given-names>C</given-names></name><name><surname>Della Porta</surname><given-names>G</given-names></name></person-group><article-title>TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas</article-title><source>Oncogene</source><year>1992</year><volume>7</volume><issue>2</issue><fpage>237</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">1532241</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butti</surname><given-names>MG</given-names></name><name><surname>Bongarzone</surname><given-names>I</given-names></name><name><surname>Ferraresi</surname><given-names>G</given-names></name><name><surname>Mondellini</surname><given-names>P</given-names></name><name><surname>Borrello</surname><given-names>MG</given-names></name><name><surname>Pierotti</surname><given-names>MA</given-names></name></person-group><article-title>A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas</article-title><source>Genomics</source><year>1995</year><volume>28</volume><issue>1</issue><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">7590742</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tognon</surname><given-names>C</given-names></name><name><surname>Knezevich</surname><given-names>SR</given-names></name><name><surname>Huntsman</surname><given-names>D</given-names></name><name><surname>Roskelley</surname><given-names>CD</given-names></name><name><surname>Melnyk</surname><given-names>N</given-names></name><name><surname>Mathers</surname><given-names>JA</given-names></name><name><surname>Becker</surname><given-names>L</given-names></name><name><surname>Carneiro</surname><given-names>F</given-names></name><name><surname>MacPherson</surname><given-names>N</given-names></name><name><surname>Horsman</surname><given-names>D</given-names></name><name><surname>Poremba</surname><given-names>C</given-names></name><name><surname>Sorensen</surname><given-names>PH</given-names></name></person-group><article-title>Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma</article-title><source>Cancer Cell</source><year>2002</year><volume>2</volume><issue>5</issue><fpage>367</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">12450792</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knezevich</surname><given-names>SR</given-names></name><name><surname>McFadden</surname><given-names>DE</given-names></name><name><surname>Tao</surname><given-names>W</given-names></name><name><surname>Lim</surname><given-names>JF</given-names></name><name><surname>Sorensen</surname><given-names>PH</given-names></name></person-group><article-title>A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma</article-title><source>Nature genetics</source><year>1998</year><volume>18</volume><issue>2</issue><fpage>184</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">9462753</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blume-Jensen</surname><given-names>P</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name></person-group><article-title>Oncogenic kinase signalling</article-title><source>Nature</source><year>2001</year><volume>411</volume><issue>6835</issue><fpage>355</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">11357143</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>DS</given-names></name><name><surname>Van Etten</surname><given-names>RA</given-names></name></person-group><article-title>Tyrosine kinases as targets for cancer therapy</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><issue>2</issue><fpage>172</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">16014887</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>AT</given-names></name><name><surname>Hsu</surname><given-names>PP</given-names></name><name><surname>Awad</surname><given-names>MM</given-names></name><name><surname>Engelman</surname><given-names>JA</given-names></name></person-group><article-title>Tyrosine kinase gene rearrangements in epithelial malignancies</article-title><source>Nature reviews Cancer</source><year>2013</year><volume>13</volume><issue>11</issue><fpage>772</fpage><lpage>787</lpage><pub-id pub-id-type="pmid">24132104</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buitenhuis</surname><given-names>M</given-names></name><name><surname>Verhagen</surname><given-names>LP</given-names></name><name><surname>Cools</surname><given-names>J</given-names></name><name><surname>Coffer</surname><given-names>PJ</given-names></name></person-group><article-title>Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><issue>8</issue><fpage>3759</fpage><lpage>3766</lpage><pub-id pub-id-type="pmid">17440089</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Sanchez-Aguilera</surname><given-names>A</given-names></name><name><surname>Brandt</surname><given-names>EB</given-names></name><name><surname>McBride</surname><given-names>M</given-names></name><name><surname>Al-Moamen</surname><given-names>NJ</given-names></name><name><surname>Finkelman</surname><given-names>FD</given-names></name><name><surname>Williams</surname><given-names>DA</given-names></name><name><surname>Cancelas</surname><given-names>JA</given-names></name><name><surname>Rothenberg</surname><given-names>ME</given-names></name></person-group><article-title>FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome</article-title><source>Blood</source><year>2008</year><volume>112</volume><issue>6</issue><fpage>2500</fpage><lpage>2507</lpage><pub-id pub-id-type="pmid">18539901</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daley</surname><given-names>GQ</given-names></name><name><surname>Van Etten</surname><given-names>RA</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><article-title>Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome</article-title><source>Science</source><year>1990</year><volume>247</volume><issue>4944</issue><fpage>824</fpage><lpage>830</lpage><pub-id pub-id-type="pmid">2406902</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elefanty</surname><given-names>AG</given-names></name><name><surname>Hariharan</surname><given-names>IK</given-names></name><name><surname>Cory</surname><given-names>S</given-names></name></person-group><article-title>bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice</article-title><source>EMBO J</source><year>1990</year><volume>9</volume><issue>4</issue><fpage>1069</fpage><lpage>1078</lpage><pub-id pub-id-type="pmid">1691092</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Etten</surname><given-names>RA</given-names></name></person-group><article-title>Models of chronic myeloid leukemia</article-title><source>Curr Oncol Rep</source><year>2001</year><volume>3</volume><issue>3</issue><fpage>228</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">11296133</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>SB</given-names></name><name><surname>Hildenbrand</surname><given-names>ZL</given-names></name><name><surname>Soyombo</surname><given-names>AA</given-names></name><name><surname>Magee</surname><given-names>JA</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Oravecz-Wilson</surname><given-names>KI</given-names></name><name><surname>Ross</surname><given-names>TS</given-names></name></person-group><article-title>Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia</article-title><source>Cell Rep</source><year>2013</year><volume>5</volume><issue>1</issue><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">24095735</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ismail</surname><given-names>SI</given-names></name><name><surname>Naffa</surname><given-names>RG</given-names></name><name><surname>Yousef</surname><given-names>AM</given-names></name><name><surname>Ghanim</surname><given-names>MT</given-names></name></person-group><article-title>Incidence of bcrabl fusion transcripts in healthy individuals</article-title><source>Mol Med Rep</source><year>2014</year><volume>9</volume><issue>4</issue><fpage>1271</fpage><lpage>1276</lpage><pub-id pub-id-type="pmid">24535287</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahon</surname><given-names>FX</given-names></name><name><surname>Rea</surname><given-names>D</given-names></name><name><surname>Guilhot</surname><given-names>J</given-names></name><name><surname>Guilhot</surname><given-names>F</given-names></name><name><surname>Huguet</surname><given-names>F</given-names></name><name><surname>Nicolini</surname><given-names>F</given-names></name><name><surname>Legros</surname><given-names>L</given-names></name><name><surname>Charbonnier</surname><given-names>A</given-names></name><name><surname>Guerci</surname><given-names>A</given-names></name><name><surname>Varet</surname><given-names>B</given-names></name><name><surname>Etienne</surname><given-names>G</given-names></name><name><surname>Reiffers</surname><given-names>J</given-names></name><name><surname>Rousselot</surname><given-names>P</given-names></name><collab>Intergroupe Francais des Leucemies Myeloides C</collab></person-group><article-title>Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial</article-title><source>Lancet Oncol</source><year>2010</year><volume>11</volume><issue>11</issue><fpage>1029</fpage><lpage>1035</lpage><pub-id pub-id-type="pmid">20965785</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>RT</given-names></name><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group><article-title>The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia</article-title><source>Adv Exp Med Biol</source><year>2007</year><volume>604</volume><fpage>107</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">17695724</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iacobucci</surname><given-names>I</given-names></name><name><surname>Ferrari</surname><given-names>A</given-names></name><name><surname>Lonetti</surname><given-names>A</given-names></name><name><surname>Papayannidis</surname><given-names>C</given-names></name><name><surname>Paoloni</surname><given-names>F</given-names></name><name><surname>Trino</surname><given-names>S</given-names></name><name><surname>Storlazzi</surname><given-names>CT</given-names></name><name><surname>Ottaviani</surname><given-names>E</given-names></name><name><surname>Cattina</surname><given-names>F</given-names></name><name><surname>Impera</surname><given-names>L</given-names></name><name><surname>Abbenante</surname><given-names>MC</given-names></name><name><surname>Vignetti</surname><given-names>M</given-names></name><name><surname>Vitale</surname><given-names>A</given-names></name><name><surname>Potenza</surname><given-names>L</given-names></name><name><surname>Paolini</surname><given-names>S</given-names></name><name><surname>Soverini</surname><given-names>S</given-names></name><etal/></person-group><article-title>CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients</article-title><source>Clinical cancer research</source><year>2011</year><volume>17</volume><issue>23</issue><fpage>7413</fpage><lpage>7423</lpage><pub-id pub-id-type="pmid">22134481</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name></person-group><article-title>Restoration of INK4a/ARF gene inhibits cell growth and cooperates with imatinib mesylate in Philadelphia chromosome-positive leukemias</article-title><source>Oncology research</source><year>2013</year><volume>21</volume><issue>1</issue><fpage>23</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">24330849</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurtz</surname><given-names>C</given-names></name><name><surname>Hatzi</surname><given-names>K</given-names></name><name><surname>Cerchietti</surname><given-names>L</given-names></name><name><surname>Braig</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Herzog</surname><given-names>S</given-names></name><name><surname>Ramezani-Rad</surname><given-names>P</given-names></name><name><surname>Jumaa</surname><given-names>H</given-names></name><name><surname>Muller</surname><given-names>MC</given-names></name><name><surname>Hofmann</surname><given-names>WK</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Ye</surname><given-names>BH</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Druker</surname><given-names>BJ</given-names></name><name><surname>Shah</surname><given-names>NP</given-names></name><etal/></person-group><article-title>BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia</article-title><source>J Exp Med</source><year>2011</year><volume>208</volume><issue>11</issue><fpage>2163</fpage><lpage>2174</lpage><pub-id pub-id-type="pmid">21911423</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>TY</given-names></name><name><surname>Ezelle</surname><given-names>HJ</given-names></name><name><surname>Venkataraman</surname><given-names>T</given-names></name><name><surname>Lapidus</surname><given-names>RG</given-names></name><name><surname>Scheibner</surname><given-names>KA</given-names></name><name><surname>Hassel</surname><given-names>BA</given-names></name></person-group><article-title>Regulation of human RNase-L by the miR-29 family reveals a novel oncogenic role in chronic myelogenous leukemia</article-title><source>J Interferon Cytokine Res</source><year>2013</year><volume>33</volume><issue>1</issue><fpage>34</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">23113544</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albers</surname><given-names>C</given-names></name><name><surname>Illert</surname><given-names>AL</given-names></name><name><surname>Miething</surname><given-names>C</given-names></name><name><surname>Leischner</surname><given-names>H</given-names></name><name><surname>Thiede</surname><given-names>M</given-names></name><name><surname>Peschel</surname><given-names>C</given-names></name><name><surname>Duyster</surname><given-names>J</given-names></name></person-group><article-title>An RNAi-based system for loss-of-function analysis identifies Raf1 as a crucial mediator of BCR-ABL-driven leukemogenesis</article-title><source>Blood</source><year>2011</year><volume>118</volume><issue>8</issue><fpage>2200</fpage><lpage>2210</lpage><pub-id pub-id-type="pmid">21715303</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Churchman</surname><given-names>ML</given-names></name><name><surname>Low</surname><given-names>J</given-names></name><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Paietta</surname><given-names>EM</given-names></name><name><surname>Kasper</surname><given-names>LH</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Payne-Turner</surname><given-names>D</given-names></name><name><surname>Althoff</surname><given-names>MJ</given-names></name><name><surname>Song</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>SC</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Rusch</surname><given-names>M</given-names></name><name><surname>McGoldrick</surname><given-names>D</given-names></name><name><surname>Edmonson</surname><given-names>M</given-names></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>YD</given-names></name><etal/></person-group><article-title>Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia</article-title><source>Cancer Cell</source><year>2015</year><volume>28</volume><issue>3</issue><fpage>343</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">26321221</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Wei</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Roy</surname><given-names>D</given-names></name><name><surname>Xiong</surname><given-names>QB</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Medvec</surname><given-names>A</given-names></name><name><surname>Danet-Desnoyers</surname><given-names>G</given-names></name><name><surname>Watt</surname><given-names>C</given-names></name><name><surname>Tomczak</surname><given-names>E</given-names></name><name><surname>Kalos</surname><given-names>M</given-names></name><name><surname>Riley</surname><given-names>JL</given-names></name><name><surname>Wasik</surname><given-names>MA</given-names></name></person-group><article-title>The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes</article-title><source>Am J Pathol</source><year>2013</year><volume>183</volume><issue>6</issue><fpage>1971</fpage><lpage>1980</lpage><pub-id pub-id-type="pmid">24404580</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maes</surname><given-names>B</given-names></name><name><surname>Vanhentenrijk</surname><given-names>V</given-names></name><name><surname>Wlodarska</surname><given-names>I</given-names></name><name><surname>Cools</surname><given-names>J</given-names></name><name><surname>Peeters</surname><given-names>B</given-names></name><name><surname>Marynen</surname><given-names>P</given-names></name><name><surname>de Wolf-Peeters</surname><given-names>C</given-names></name></person-group><article-title>The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells</article-title><source>Am J Pathol</source><year>2001</year><volume>158</volume><issue>6</issue><fpage>2185</fpage><lpage>2193</lpage><pub-id pub-id-type="pmid">11395396</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boland</surname><given-names>JM</given-names></name><name><surname>Jang</surname><given-names>JS</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>AM</given-names></name><name><surname>Wampfler</surname><given-names>JA</given-names></name><name><surname>Erickson-Johnson</surname><given-names>MR</given-names></name><name><surname>Soares</surname><given-names>I</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Jen</surname><given-names>J</given-names></name><name><surname>Oliveira</surname><given-names>AM</given-names></name><name><surname>Yi</surname><given-names>ES</given-names></name></person-group><article-title>MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases</article-title><source>J Thorac Oncol</source><year>2013</year><volume>8</volume><issue>5</issue><fpage>574</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">23449277</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jankovic</surname><given-names>GM</given-names></name><name><surname>Pavlovic</surname><given-names>M</given-names></name><name><surname>Vukomanovic</surname><given-names>DJ</given-names></name><name><surname>Colovic</surname><given-names>MD</given-names></name><name><surname>Lazarevic</surname><given-names>V</given-names></name></person-group><article-title>The fundamental prevalence of chronic myeloid leukemia-generating clonogenic cells in the light of the neutrality theory of evolution</article-title><source>Blood Cells Mol Dis</source><year>2001</year><volume>27</volume><issue>5</issue><fpage>913</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">11783955</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baccarani</surname><given-names>M</given-names></name><name><surname>Cilloni</surname><given-names>D</given-names></name><name><surname>Rondoni</surname><given-names>M</given-names></name><name><surname>Ottaviani</surname><given-names>E</given-names></name><name><surname>Messa</surname><given-names>F</given-names></name><name><surname>Merante</surname><given-names>S</given-names></name><name><surname>Tiribelli</surname><given-names>M</given-names></name><name><surname>Buccisano</surname><given-names>F</given-names></name><name><surname>Testoni</surname><given-names>N</given-names></name><name><surname>Gottardi</surname><given-names>E</given-names></name><name><surname>de Vivo</surname><given-names>A</given-names></name><name><surname>Giugliano</surname><given-names>E</given-names></name><name><surname>Iacobucci</surname><given-names>I</given-names></name><name><surname>Paolini</surname><given-names>S</given-names></name><name><surname>Soverini</surname><given-names>S</given-names></name><name><surname>Rosti</surname><given-names>G</given-names></name><etal/></person-group><article-title>The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study</article-title><source>Haematologica</source><year>2007</year><volume>92</volume><issue>9</issue><fpage>1173</fpage><lpage>1179</lpage><pub-id pub-id-type="pmid">17666373</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baccarani</surname><given-names>M</given-names></name><name><surname>Deininger</surname><given-names>MW</given-names></name><name><surname>Rosti</surname><given-names>G</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Soverini</surname><given-names>S</given-names></name><name><surname>Apperley</surname><given-names>JF</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Clark</surname><given-names>RE</given-names></name><name><surname>Cortes</surname><given-names>JE</given-names></name><name><surname>Guilhot</surname><given-names>F</given-names></name><name><surname>Hjorth-Hansen</surname><given-names>H</given-names></name><name><surname>Hughes</surname><given-names>TP</given-names></name><name><surname>Kantarjian</surname><given-names>HM</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Larson</surname><given-names>RA</given-names></name><name><surname>Lipton</surname><given-names>JH</given-names></name><etal/></person-group><article-title>European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013</article-title><source>Blood</source><year>2013</year><volume>122</volume><issue>6</issue><fpage>872</fpage><lpage>884</lpage><pub-id pub-id-type="pmid">23803709</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camidge</surname><given-names>DR</given-names></name><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Kwak</surname><given-names>EL</given-names></name><name><surname>Iafrate</surname><given-names>AJ</given-names></name><name><surname>Varella-Garcia</surname><given-names>M</given-names></name><name><surname>Fox</surname><given-names>SB</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><name><surname>Solomon</surname><given-names>B</given-names></name><name><surname>Ou</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Salgia</surname><given-names>R</given-names></name><name><surname>Fidias</surname><given-names>P</given-names></name><name><surname>Engelman</surname><given-names>JA</given-names></name><name><surname>Gandhi</surname><given-names>L</given-names></name><name><surname>Janne</surname><given-names>PA</given-names></name><name><surname>Costa</surname><given-names>DB</given-names></name><etal/></person-group><article-title>Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study</article-title><source>Lancet Oncol</source><year>2012</year><volume>13</volume><issue>10</issue><fpage>1011</fpage><lpage>1019</lpage><pub-id pub-id-type="pmid">22954507</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lovly</surname><given-names>CM</given-names></name><name><surname>McDonald</surname><given-names>NT</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Ortiz-Cuaran</surname><given-names>S</given-names></name><name><surname>Heukamp</surname><given-names>LC</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Florin</surname><given-names>A</given-names></name><name><surname>Ozretic</surname><given-names>L</given-names></name><name><surname>Lim</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Paik</surname><given-names>PK</given-names></name><name><surname>Shen</surname><given-names>R</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><etal/></person-group><article-title>Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer</article-title><source>Nature medicine</source><year>2014</year><volume>20</volume><issue>9</issue><fpage>1027</fpage><lpage>1034</lpage></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottmann</surname><given-names>OG</given-names></name><name><surname>Wassmann</surname><given-names>B</given-names></name></person-group><article-title>Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia</article-title><source>Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program</source><year>2005</year><fpage>118</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">16304368</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boi</surname><given-names>M</given-names></name><name><surname>Rinaldi</surname><given-names>A</given-names></name><name><surname>Kwee</surname><given-names>I</given-names></name><name><surname>Bonetti</surname><given-names>P</given-names></name><name><surname>Todaro</surname><given-names>M</given-names></name><name><surname>Tabbo</surname><given-names>F</given-names></name><name><surname>Piva</surname><given-names>R</given-names></name><name><surname>Rancoita</surname><given-names>PM</given-names></name><name><surname>Matolcsy</surname><given-names>A</given-names></name><name><surname>Timar</surname><given-names>B</given-names></name><name><surname>Tousseyn</surname><given-names>T</given-names></name><name><surname>Rodriguez-Pinilla</surname><given-names>SM</given-names></name><name><surname>Piris</surname><given-names>MA</given-names></name><name><surname>Bea</surname><given-names>S</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>Bhagat</surname><given-names>G</given-names></name><etal/></person-group><article-title>PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma</article-title><source>Blood</source><year>2013</year><volume>122</volume><issue>15</issue><fpage>2683</fpage><lpage>2693</lpage><pub-id pub-id-type="pmid">24004669</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakshmikuttyamma</surname><given-names>A</given-names></name><name><surname>Pastural</surname><given-names>E</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Sawada</surname><given-names>K</given-names></name><name><surname>Sheridan</surname><given-names>DP</given-names></name><name><surname>DeCoteau</surname><given-names>JF</given-names></name><name><surname>Geyer</surname><given-names>CR</given-names></name></person-group><article-title>Bcr-Abl induces autocrine IGF-1 signaling</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><issue>27</issue><fpage>3831</fpage><lpage>3844</lpage><pub-id pub-id-type="pmid">18246120</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stover</surname><given-names>EH</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Folens</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>BH</given-names></name><name><surname>Mentens</surname><given-names>N</given-names></name><name><surname>Marynen</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>IR</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name><name><surname>Cools</surname><given-names>J</given-names></name></person-group><article-title>Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><issue>21</issue><fpage>8078</fpage><lpage>8083</lpage><pub-id pub-id-type="pmid">16690743</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toffalini</surname><given-names>F</given-names></name><name><surname>Demoulin</surname><given-names>JB</given-names></name></person-group><article-title>New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases</article-title><source>Blood</source><year>2010</year><volume>116</volume><issue>14</issue><fpage>2429</fpage><lpage>2437</lpage><pub-id pub-id-type="pmid">20581310</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Etten</surname><given-names>RA</given-names></name></person-group><article-title>Oncogenic signaling: new insights and controversies from chronic myeloid leukemia</article-title><source>J Exp Med</source><year>2007</year><volume>204</volume><issue>3</issue><fpage>461</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">17353369</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotlib</surname><given-names>J</given-names></name></person-group><article-title>World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management</article-title><source>American journal of hematology</source><year>2015</year><volume>90</volume><issue>11</issue><fpage>1077</fpage><lpage>1089</lpage><pub-id pub-id-type="pmid">26486351</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiarle</surname><given-names>R</given-names></name><name><surname>Voena</surname><given-names>C</given-names></name><name><surname>Ambrogio</surname><given-names>C</given-names></name><name><surname>Piva</surname><given-names>R</given-names></name><name><surname>Inghirami</surname><given-names>G</given-names></name></person-group><article-title>The anaplastic lymphoma kinase in the pathogenesis of cancer</article-title><source>Nature reviews Cancer</source><year>2008</year><volume>8</volume><issue>1</issue><fpage>11</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">18097461</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Streubel</surname><given-names>B</given-names></name><name><surname>Vinatzer</surname><given-names>U</given-names></name><name><surname>Willheim</surname><given-names>M</given-names></name><name><surname>Raderer</surname><given-names>M</given-names></name><name><surname>Chott</surname><given-names>A</given-names></name></person-group><article-title>Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma</article-title><source>Leukemia</source><year>2006</year><volume>20</volume><issue>2</issue><fpage>313</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">16341044</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pechloff</surname><given-names>K</given-names></name><name><surname>Holch</surname><given-names>J</given-names></name><name><surname>Ferch</surname><given-names>U</given-names></name><name><surname>Schweneker</surname><given-names>M</given-names></name><name><surname>Brunner</surname><given-names>K</given-names></name><name><surname>Kremer</surname><given-names>M</given-names></name><name><surname>Sparwasser</surname><given-names>T</given-names></name><name><surname>Quintanilla-Martinez</surname><given-names>L</given-names></name><name><surname>Zimber-Strobl</surname><given-names>U</given-names></name><name><surname>Streubel</surname><given-names>B</given-names></name><name><surname>Gewies</surname><given-names>A</given-names></name><name><surname>Peschel</surname><given-names>C</given-names></name><name><surname>Ruland</surname><given-names>J</given-names></name></person-group><article-title>The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma</article-title><source>J Exp Med</source><year>2010</year><volume>207</volume><issue>5</issue><fpage>1031</fpage><lpage>1044</lpage><pub-id pub-id-type="pmid">20439541</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiarle</surname><given-names>R</given-names></name><name><surname>Gong</surname><given-names>JZ</given-names></name><name><surname>Guasparri</surname><given-names>I</given-names></name><name><surname>Pesci</surname><given-names>A</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Simmons</surname><given-names>WJ</given-names></name><name><surname>Dhall</surname><given-names>G</given-names></name><name><surname>Howes</surname><given-names>J</given-names></name><name><surname>Piva</surname><given-names>R</given-names></name><name><surname>Inghirami</surname><given-names>G</given-names></name></person-group><article-title>NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors</article-title><source>Blood</source><year>2003</year><volume>101</volume><issue>5</issue><fpage>1919</fpage><lpage>1927</lpage><pub-id pub-id-type="pmid">12424201</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamo</surname><given-names>A</given-names></name><name><surname>Chiarle</surname><given-names>R</given-names></name><name><surname>Piva</surname><given-names>R</given-names></name><name><surname>Howes</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Chilosi</surname><given-names>M</given-names></name><name><surname>Levy</surname><given-names>DE</given-names></name><name><surname>Inghirami</surname><given-names>G</given-names></name></person-group><article-title>Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><issue>7</issue><fpage>1038</fpage><lpage>1047</lpage><pub-id pub-id-type="pmid">11850821</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velusamy</surname><given-names>T</given-names></name><name><surname>Kiel</surname><given-names>MJ</given-names></name><name><surname>Sahasrabuddhe</surname><given-names>AA</given-names></name><name><surname>Rolland</surname><given-names>D</given-names></name><name><surname>Dixon</surname><given-names>CA</given-names></name><name><surname>Bailey</surname><given-names>NG</given-names></name><name><surname>Betz</surname><given-names>BL</given-names></name><name><surname>Brown</surname><given-names>NA</given-names></name><name><surname>Hristov</surname><given-names>AC</given-names></name><name><surname>Wilcox</surname><given-names>RA</given-names></name><name><surname>Miranda</surname><given-names>RN</given-names></name><name><surname>Medeiros</surname><given-names>LJ</given-names></name><name><surname>Jeon</surname><given-names>YK</given-names></name><name><surname>Inamdar</surname><given-names>KV</given-names></name><name><surname>Lim</surname><given-names>MS</given-names></name><name><surname>Elenitoba-Johnson</surname><given-names>KS</given-names></name></person-group><article-title>A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders</article-title><source>Blood</source><year>2014</year><volume>124</volume><issue>25</issue><fpage>3768</fpage><lpage>3771</lpage><pub-id pub-id-type="pmid">25349176</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagemeijer</surname><given-names>A</given-names></name><name><surname>Graux</surname><given-names>C</given-names></name></person-group><article-title>ABL1 rearrangements in T-cell acute lymphoblastic leukemia</article-title><source>Genes, chromosomes &#x00026; cancer</source><year>2010</year><volume>49</volume><issue>4</issue><fpage>299</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">20073070</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tefferi</surname><given-names>A</given-names></name><name><surname>Elliott</surname><given-names>M</given-names></name><name><surname>Pardanani</surname><given-names>A</given-names></name></person-group><article-title>Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice</article-title><source>Current opinion in hematology</source><year>2015</year><volume>22</volume><issue>2</issue><fpage>171</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">25575036</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintas-Cardama</surname><given-names>A</given-names></name><name><surname>Verstovsek</surname><given-names>S</given-names></name></person-group><article-title>Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance</article-title><source>Clinical cancer research</source><year>2013</year><volume>19</volume><issue>8</issue><fpage>1933</fpage><lpage>1940</lpage><pub-id pub-id-type="pmid">23406773</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bubala</surname><given-names>H</given-names></name><name><surname>Maldyk</surname><given-names>J</given-names></name><name><surname>Wlodarska</surname><given-names>I</given-names></name><name><surname>Sonta-Jakimczyk</surname><given-names>D</given-names></name><name><surname>Szczepanski</surname><given-names>T</given-names></name></person-group><article-title>ALK-positive diffuse large B-cell lymphoma</article-title><source>Pediatr Blood Cancer</source><year>2006</year><volume>46</volume><issue>5</issue><fpage>649</fpage><lpage>653</lpage><pub-id pub-id-type="pmid">15852431</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizuki</surname><given-names>M</given-names></name><name><surname>Ueda</surname><given-names>S</given-names></name><name><surname>Matsumura</surname><given-names>I</given-names></name><name><surname>Ishiko</surname><given-names>J</given-names></name><name><surname>Schwable</surname><given-names>J</given-names></name><name><surname>Serve</surname><given-names>H</given-names></name><name><surname>Kanakura</surname><given-names>Y</given-names></name></person-group><article-title>Oncogenic receptor tyrosine kinase in leukemia</article-title><source>Cell Mol Biol (Noisy-le-grand)</source><year>2003</year><volume>49</volume><issue>6</issue><fpage>907</fpage><lpage>922</lpage><pub-id pub-id-type="pmid">14656048</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zandi</surname><given-names>R</given-names></name><name><surname>Larsen</surname><given-names>AB</given-names></name><name><surname>Andersen</surname><given-names>P</given-names></name><name><surname>Stockhausen</surname><given-names>MT</given-names></name><name><surname>Poulsen</surname><given-names>HS</given-names></name></person-group><article-title>Mechanisms for oncogenic activation of the epidermal growth factor receptor</article-title><source>Cell Signal</source><year>2007</year><volume>19</volume><issue>10</issue><fpage>2013</fpage><lpage>2023</lpage><pub-id pub-id-type="pmid">17681753</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiesner</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Obenauf</surname><given-names>AC</given-names></name><name><surname>Ran</surname><given-names>L</given-names></name><name><surname>Murali</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>QF</given-names></name><name><surname>Wong</surname><given-names>EW</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Scott</surname><given-names>SN</given-names></name><name><surname>Shah</surname><given-names>RH</given-names></name><name><surname>Landa</surname><given-names>I</given-names></name><name><surname>Button</surname><given-names>J</given-names></name><name><surname>Lailler</surname><given-names>N</given-names></name><name><surname>Sboner</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Alternative transcription initiation leads to expression of a novel ALK isoform in cancer</article-title><source>Nature</source><year>2015</year><volume>526</volume><issue>7573</issue><fpage>453</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">26444240</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scarfo</surname><given-names>I</given-names></name><name><surname>Pellegrino</surname><given-names>E</given-names></name><name><surname>Mereu</surname><given-names>E</given-names></name><name><surname>Kwee</surname><given-names>I</given-names></name><name><surname>Agnelli</surname><given-names>L</given-names></name><name><surname>Bergaggio</surname><given-names>E</given-names></name><name><surname>Garaffo</surname><given-names>G</given-names></name><name><surname>Vitale</surname><given-names>N</given-names></name><name><surname>Caputo</surname><given-names>M</given-names></name><name><surname>Machiorlatti</surname><given-names>R</given-names></name><name><surname>Circosta</surname><given-names>P</given-names></name><name><surname>Abate</surname><given-names>F</given-names></name><name><surname>Barreca</surname><given-names>A</given-names></name><name><surname>Novero</surname><given-names>D</given-names></name><name><surname>Mathew</surname><given-names>S</given-names></name><name><surname>Rinaldi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Identification of a new subclass of ALK negative ALCL expressing aberrant levels of ERBB4 transcripts</article-title><source>Blood</source><year>2015</year></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soda</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>YL</given-names></name><name><surname>Enomoto</surname><given-names>M</given-names></name><name><surname>Takada</surname><given-names>S</given-names></name><name><surname>Yamashita</surname><given-names>Y</given-names></name><name><surname>Ishikawa</surname><given-names>S</given-names></name><name><surname>Fujiwara</surname><given-names>S</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Kurashina</surname><given-names>K</given-names></name><name><surname>Hatanaka</surname><given-names>H</given-names></name><name><surname>Bando</surname><given-names>M</given-names></name><name><surname>Ohno</surname><given-names>S</given-names></name><name><surname>Ishikawa</surname><given-names>Y</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><name><surname>Niki</surname><given-names>T</given-names></name><name><surname>Sohara</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</article-title><source>Nature</source><year>2007</year><volume>448</volume><issue>7153</issue><fpage>561</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">17625570</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hrustanovic</surname><given-names>G</given-names></name><name><surname>Olivas</surname><given-names>V</given-names></name><name><surname>Pazarentzos</surname><given-names>E</given-names></name><name><surname>Tulpule</surname><given-names>A</given-names></name><name><surname>Asthana</surname><given-names>S</given-names></name><name><surname>Blakely</surname><given-names>CM</given-names></name><name><surname>Okimoto</surname><given-names>RA</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Neel</surname><given-names>DS</given-names></name><name><surname>Sabnis</surname><given-names>A</given-names></name><name><surname>Flanagan</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>E</given-names></name><name><surname>Varella-Garcia</surname><given-names>M</given-names></name><name><surname>Aisner</surname><given-names>DL</given-names></name><name><surname>Vaishnavi</surname><given-names>A</given-names></name><name><surname>Ou</surname><given-names>SH</given-names></name><etal/></person-group><article-title>RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer</article-title><source>Nature medicine</source><year>2015</year><volume>21</volume><issue>9</issue><fpage>1038</fpage><lpage>1047</lpage></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>SV</given-names></name><name><surname>Settleman</surname><given-names>J</given-names></name></person-group><article-title>Oncogene addiction: setting the stage for molecularly targeted cancer therapy</article-title><source>Genes &#x00026; development</source><year>2007</year><volume>21</volume><issue>24</issue><fpage>3214</fpage><lpage>3231</lpage><pub-id pub-id-type="pmid">18079171</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>SH</given-names></name><name><surname>Soo</surname><given-names>RA</given-names></name><name><surname>Kubo</surname><given-names>A</given-names></name><name><surname>Kawaguchi</surname><given-names>T</given-names></name><name><surname>Ahn</surname><given-names>MJ</given-names></name></person-group><article-title>Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-alpha-, NTRK1-) Non-Small Cell Lung Cancer Globally?</article-title><source>Front Oncol</source><year>2014</year><volume>4</volume><fpage>58</fpage><pub-id pub-id-type="pmid">24744988</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rikova</surname><given-names>K</given-names></name><name><surname>Guo</surname><given-names>A</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Possemato</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Haack</surname><given-names>H</given-names></name><name><surname>Nardone</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Reeves</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>Z</given-names></name><name><surname>Stokes</surname><given-names>M</given-names></name><name><surname>Sullivan</surname><given-names>L</given-names></name><name><surname>Mitchell</surname><given-names>J</given-names></name><name><surname>Wetzel</surname><given-names>R</given-names></name><etal/></person-group><article-title>Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer</article-title><source>Cell</source><year>2007</year><volume>131</volume><issue>6</issue><fpage>1190</fpage><lpage>1203</lpage><pub-id pub-id-type="pmid">18083107</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>TL</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Tucker</surname><given-names>M</given-names></name><name><surname>Crosby</surname><given-names>K</given-names></name><name><surname>Rimkunas</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>G</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Tan</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Nardone</surname><given-names>J</given-names></name><name><surname>MacNeill</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Reeves</surname><given-names>C</given-names></name><etal/></person-group><article-title>Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><issue>1</issue><fpage>e15640</fpage><pub-id pub-id-type="pmid">21253578</pub-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>MJ</given-names></name><name><surname>Cox</surname><given-names>NJ</given-names></name><name><surname>Zimmerman</surname><given-names>EI</given-names></name><name><surname>Dewar</surname><given-names>BJ</given-names></name><name><surname>Duncan</surname><given-names>JS</given-names></name><name><surname>Whittle</surname><given-names>MC</given-names></name><name><surname>Nguyen</surname><given-names>TA</given-names></name><name><surname>Jones</surname><given-names>LS</given-names></name><name><surname>Ghose Roy</surname><given-names>S</given-names></name><name><surname>Smalley</surname><given-names>DM</given-names></name><name><surname>Kuan</surname><given-names>PF</given-names></name><name><surname>Richards</surname><given-names>KL</given-names></name><name><surname>Christopherson</surname><given-names>RI</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Frye</surname><given-names>SV</given-names></name><name><surname>Johnson</surname><given-names>GL</given-names></name><etal/></person-group><article-title>Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>6</issue><fpage>e66755</fpage><pub-id pub-id-type="pmid">23826126</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagisawa</surname><given-names>K</given-names></name><name><surname>Tomida</surname><given-names>S</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Yatabe</surname><given-names>Y</given-names></name><name><surname>Mitsudomi</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name></person-group><article-title>A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer</article-title><source>J Natl Cancer Inst</source><year>2007</year><volume>99</volume><issue>11</issue><fpage>858</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">17551146</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Diaz</surname><given-names>AK</given-names></name><name><surname>Paugh</surname><given-names>BS</given-names></name><name><surname>Rankin</surname><given-names>SL</given-names></name><name><surname>Ju</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Qu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Easton</surname><given-names>J</given-names></name><name><surname>Edmonson</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Nagahawatte</surname><given-names>P</given-names></name><name><surname>Hedlund</surname><given-names>E</given-names></name><etal/></person-group><article-title>The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma</article-title><source>Nature genetics</source><year>2014</year><volume>46</volume><issue>5</issue><fpage>444</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">24705251</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frattini</surname><given-names>V</given-names></name><name><surname>Trifonov</surname><given-names>V</given-names></name><name><surname>Chan</surname><given-names>JM</given-names></name><name><surname>Castano</surname><given-names>A</given-names></name><name><surname>Lia</surname><given-names>M</given-names></name><name><surname>Abate</surname><given-names>F</given-names></name><name><surname>Keir</surname><given-names>ST</given-names></name><name><surname>Ji</surname><given-names>AX</given-names></name><name><surname>Zoppoli</surname><given-names>P</given-names></name><name><surname>Niola</surname><given-names>F</given-names></name><name><surname>Danussi</surname><given-names>C</given-names></name><name><surname>Dolgalev</surname><given-names>I</given-names></name><name><surname>Porrati</surname><given-names>P</given-names></name><name><surname>Pellegatta</surname><given-names>S</given-names></name><name><surname>Heguy</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>G</given-names></name><etal/></person-group><article-title>The integrated landscape of driver genomic alterations in glioblastoma</article-title><source>Nature genetics</source><year>2013</year><volume>45</volume><issue>10</issue><fpage>1141</fpage><lpage>1149</lpage><pub-id pub-id-type="pmid">23917401</pub-id></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seshagiri</surname><given-names>S</given-names></name><name><surname>Stawiski</surname><given-names>EW</given-names></name><name><surname>Durinck</surname><given-names>S</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Storm</surname><given-names>EE</given-names></name><name><surname>Conboy</surname><given-names>CB</given-names></name><name><surname>Chaudhuri</surname><given-names>S</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Janakiraman</surname><given-names>V</given-names></name><name><surname>Jaiswal</surname><given-names>BS</given-names></name><name><surname>Guillory</surname><given-names>J</given-names></name><name><surname>Ha</surname><given-names>C</given-names></name><name><surname>Dijkgraaf</surname><given-names>GJ</given-names></name><name><surname>Stinson</surname><given-names>J</given-names></name><name><surname>Gnad</surname><given-names>F</given-names></name><name><surname>Huntley</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Recurrent R-spondin fusions in colon cancer</article-title><source>Nature</source><year>2012</year><volume>488</volume><issue>7413</issue><fpage>660</fpage><lpage>664</lpage><pub-id pub-id-type="pmid">22895193</pub-id></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricarte-Filho</surname><given-names>JC</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Garcia-Rendueles</surname><given-names>ME</given-names></name><name><surname>Montero-Conde</surname><given-names>C</given-names></name><name><surname>Voza</surname><given-names>F</given-names></name><name><surname>Knauf</surname><given-names>JA</given-names></name><name><surname>Heguy</surname><given-names>A</given-names></name><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>Bogdanova</surname><given-names>T</given-names></name><name><surname>Thomas</surname><given-names>GA</given-names></name><name><surname>Mason</surname><given-names>CE</given-names></name><name><surname>Fagin</surname><given-names>JA</given-names></name></person-group><article-title>Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers</article-title><source>J Clin Invest</source><year>2013</year><volume>123</volume><issue>11</issue><fpage>4935</fpage><lpage>4944</lpage><pub-id pub-id-type="pmid">24135138</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semrau</surname><given-names>S</given-names></name><name><surname>Crosetto</surname><given-names>N</given-names></name><name><surname>Bienko</surname><given-names>M</given-names></name><name><surname>Boni</surname><given-names>M</given-names></name><name><surname>Bernasconi</surname><given-names>P</given-names></name><name><surname>Chiarle</surname><given-names>R</given-names></name><name><surname>van Oudenaarden</surname><given-names>A</given-names></name></person-group><article-title>FuseFISH: robust detection of transcribed gene fusions in single cells</article-title><source>Cell Rep</source><year>2014</year><volume>6</volume><issue>1</issue><fpage>18</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">24373969</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyal</surname><given-names>E</given-names></name><name><surname>Tohami</surname><given-names>T</given-names></name><name><surname>Amir</surname><given-names>A</given-names></name><name><surname>Cesarkas</surname><given-names>K</given-names></name><name><surname>Jacob-Hirsch</surname><given-names>J</given-names></name><name><surname>Volchek</surname><given-names>Y</given-names></name><name><surname>Nagler</surname><given-names>A</given-names></name><name><surname>Rechavi</surname><given-names>G</given-names></name><name><surname>Amariglio</surname><given-names>N</given-names></name></person-group><article-title>Detection of BCR-ABL1 mutations in chronic myeloid leukaemia by massive parallel sequencing</article-title><source>Br J Haematol</source><year>2013</year><volume>160</volume><issue>4</issue><fpage>477</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">23252482</pub-id></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sholl</surname><given-names>LM</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Butaney</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Janne</surname><given-names>PA</given-names></name><name><surname>Rodig</surname><given-names>SJ</given-names></name></person-group><article-title>ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas</article-title><source>Am J Surg Pathol</source><year>2013</year><volume>37</volume><issue>9</issue><fpage>1441</fpage><lpage>1449</lpage><pub-id pub-id-type="pmid">23887156</pub-id></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lira</surname><given-names>ME</given-names></name><name><surname>Choi</surname><given-names>YL</given-names></name><name><surname>Lim</surname><given-names>SM</given-names></name><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Ozeck</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Jeong</surname><given-names>JY</given-names></name><name><surname>Shim</surname><given-names>HS</given-names></name><name><surname>Cho</surname><given-names>BC</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Ahn</surname><given-names>MJ</given-names></name><name><surname>Mao</surname><given-names>M</given-names></name></person-group><article-title>A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer</article-title><source>J Mol Diagn</source><year>2014</year><volume>16</volume><issue>2</issue><fpage>229</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">24418728</pub-id></element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>FP</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Quintas-Cardama</surname><given-names>A</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name></person-group><article-title>Evolution of therapies for chronic myelogenous leukemia</article-title><source>Cancer J</source><year>2011</year><volume>17</volume><issue>6</issue><fpage>465</fpage><lpage>476</lpage><pub-id pub-id-type="pmid">22157290</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>AT</given-names></name><name><surname>Ou</surname><given-names>SH</given-names></name><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Camidge</surname><given-names>DR</given-names></name><name><surname>Solomon</surname><given-names>BJ</given-names></name><name><surname>Salgia</surname><given-names>R</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><name><surname>Varella-Garcia</surname><given-names>M</given-names></name><name><surname>Shapiro</surname><given-names>GI</given-names></name><name><surname>Costa</surname><given-names>DB</given-names></name><name><surname>Doebele</surname><given-names>RC</given-names></name><name><surname>Le</surname><given-names>LP</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Stephenson</surname><given-names>P</given-names></name><name><surname>Shreeve</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><issue>21</issue><fpage>1963</fpage><lpage>1971</lpage><pub-id pub-id-type="pmid">25264305</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>BH</given-names></name><name><surname>Willis</surname><given-names>SG</given-names></name><name><surname>Stork</surname><given-names>L</given-names></name><name><surname>Hunger</surname><given-names>SP</given-names></name><name><surname>Carroll</surname><given-names>WL</given-names></name><name><surname>Camitta</surname><given-names>BM</given-names></name><name><surname>Winick</surname><given-names>NJ</given-names></name><name><surname>Druker</surname><given-names>BJ</given-names></name><name><surname>Schultz</surname><given-names>KR</given-names></name></person-group><article-title>Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study</article-title><source>Br J Haematol</source><year>2012</year><volume>157</volume><issue>4</issue><fpage>507</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">22299775</pub-id></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Bhatia</surname><given-names>R</given-names></name></person-group><article-title>BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><issue>14</issue><fpage>7045</fpage><lpage>7053</lpage><pub-id pub-id-type="pmid">17638918</pub-id></element-citation></ref><ref id="R93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Druker</surname><given-names>BJ</given-names></name><name><surname>Guilhot</surname><given-names>F</given-names></name><name><surname>O'Brien</surname><given-names>SG</given-names></name><name><surname>Gathmann</surname><given-names>I</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Gattermann</surname><given-names>N</given-names></name><name><surname>Deininger</surname><given-names>MW</given-names></name><name><surname>Silver</surname><given-names>RT</given-names></name><name><surname>Goldman</surname><given-names>JM</given-names></name><name><surname>Stone</surname><given-names>RM</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Powell</surname><given-names>BL</given-names></name><name><surname>Gabrilove</surname><given-names>JL</given-names></name><name><surname>Rousselot</surname><given-names>P</given-names></name><name><surname>Reiffers</surname><given-names>J</given-names></name><etal/></person-group><article-title>Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><issue>23</issue><fpage>2408</fpage><lpage>2417</lpage><pub-id pub-id-type="pmid">17151364</pub-id></element-citation></ref><ref id="R94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gambacorti-Passerini</surname><given-names>C</given-names></name><name><surname>Antolini</surname><given-names>L</given-names></name><name><surname>Mahon</surname><given-names>FX</given-names></name><name><surname>Guilhot</surname><given-names>F</given-names></name><name><surname>Deininger</surname><given-names>M</given-names></name><name><surname>Fava</surname><given-names>C</given-names></name><name><surname>Nagler</surname><given-names>A</given-names></name><name><surname>Della Casa</surname><given-names>CM</given-names></name><name><surname>Morra</surname><given-names>E</given-names></name><name><surname>Abruzzese</surname><given-names>E</given-names></name><name><surname>D'Emilio</surname><given-names>A</given-names></name><name><surname>Stagno</surname><given-names>F</given-names></name><name><surname>le Coutre</surname><given-names>P</given-names></name><name><surname>Hurtado-Monroy</surname><given-names>R</given-names></name><name><surname>Santini</surname><given-names>V</given-names></name><name><surname>Martino</surname><given-names>B</given-names></name><etal/></person-group><article-title>Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib</article-title><source>J Natl Cancer Inst</source><year>2011</year><volume>103</volume><issue>7</issue><fpage>553</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">21422402</pub-id></element-citation></ref><ref id="R95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoury</surname><given-names>HJ</given-names></name><name><surname>Cortes</surname><given-names>JE</given-names></name><name><surname>Kantarjian</surname><given-names>HM</given-names></name><name><surname>Gambacorti-Passerini</surname><given-names>C</given-names></name><name><surname>Baccarani</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Zaritskey</surname><given-names>A</given-names></name><name><surname>Countouriotis</surname><given-names>A</given-names></name><name><surname>Besson</surname><given-names>N</given-names></name><name><surname>Leip</surname><given-names>E</given-names></name><name><surname>Kelly</surname><given-names>V</given-names></name><name><surname>Brummendorf</surname><given-names>TH</given-names></name></person-group><article-title>Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure</article-title><source>Blood</source><year>2012</year><volume>119</volume><issue>15</issue><fpage>3403</fpage><lpage>3412</lpage><pub-id pub-id-type="pmid">22371878</pub-id></element-citation></ref><ref id="R96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>WW</given-names></name><name><surname>Wise</surname><given-names>SC</given-names></name><name><surname>Kaufman</surname><given-names>MD</given-names></name><name><surname>Ahn</surname><given-names>YM</given-names></name><name><surname>Ensinger</surname><given-names>CL</given-names></name><name><surname>Haack</surname><given-names>T</given-names></name><name><surname>Hood</surname><given-names>MM</given-names></name><name><surname>Jones</surname><given-names>J</given-names></name><name><surname>Lord</surname><given-names>JW</given-names></name><name><surname>Lu</surname><given-names>WP</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name><name><surname>Patt</surname><given-names>WC</given-names></name><name><surname>Smith</surname><given-names>BD</given-names></name><name><surname>Petillo</surname><given-names>PA</given-names></name><name><surname>Rutkoski</surname><given-names>TJ</given-names></name><name><surname>Telikepalli</surname><given-names>H</given-names></name><etal/></person-group><article-title>Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036</article-title><source>Cancer Cell</source><year>2011</year><volume>19</volume><issue>4</issue><fpage>556</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">21481795</pub-id></element-citation></ref><ref id="R97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortes</surname><given-names>JE</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Pinilla-Ibarz</surname><given-names>J</given-names></name><name><surname>le Coutre</surname><given-names>P</given-names></name><name><surname>Paquette</surname><given-names>R</given-names></name><name><surname>Chuah</surname><given-names>C</given-names></name><name><surname>Nicolini</surname><given-names>FE</given-names></name><name><surname>Apperley</surname><given-names>JF</given-names></name><name><surname>Khoury</surname><given-names>HJ</given-names></name><name><surname>Talpaz</surname><given-names>M</given-names></name><name><surname>DiPersio</surname><given-names>J</given-names></name><name><surname>DeAngelo</surname><given-names>DJ</given-names></name><name><surname>Abruzzese</surname><given-names>E</given-names></name><name><surname>Rea</surname><given-names>D</given-names></name><name><surname>Baccarani</surname><given-names>M</given-names></name><name><surname>Muller</surname><given-names>MC</given-names></name><etal/></person-group><article-title>A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>19</issue><fpage>1783</fpage><lpage>1796</lpage><pub-id pub-id-type="pmid">24180494</pub-id></element-citation></ref><ref id="R98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pemovska</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>E</given-names></name><name><surname>Kontro</surname><given-names>M</given-names></name><name><surname>Repasky</surname><given-names>GA</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wells</surname><given-names>P</given-names></name><name><surname>Cronin</surname><given-names>CN</given-names></name><name><surname>McTigue</surname><given-names>M</given-names></name><name><surname>Kallioniemi</surname><given-names>O</given-names></name><name><surname>Porkka</surname><given-names>K</given-names></name><name><surname>Murray</surname><given-names>BW</given-names></name><name><surname>Wennerberg</surname><given-names>K</given-names></name></person-group><article-title>Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation</article-title><source>Nature</source><year>2015</year><volume>519</volume><issue>7541</issue><fpage>102</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">25686603</pub-id></element-citation></ref><ref id="R99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Hare</surname><given-names>T</given-names></name><name><surname>Zabriskie</surname><given-names>MS</given-names></name><name><surname>Eiring</surname><given-names>AM</given-names></name><name><surname>Deininger</surname><given-names>MW</given-names></name></person-group><article-title>Pushing the limits of targeted therapy in chronic myeloid leukaemia</article-title><source>Nature reviews Cancer</source><year>2012</year><volume>12</volume><issue>8</issue><fpage>513</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">22825216</pub-id></element-citation></ref><ref id="R100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eiring</surname><given-names>AM</given-names></name><name><surname>Page</surname><given-names>BD</given-names></name><name><surname>Kraft</surname><given-names>IL</given-names></name><name><surname>Mason</surname><given-names>CC</given-names></name><name><surname>Vellore</surname><given-names>NA</given-names></name><name><surname>Resetca</surname><given-names>D</given-names></name><name><surname>Zabriskie</surname><given-names>MS</given-names></name><name><surname>Zhang</surname><given-names>TY</given-names></name><name><surname>Khorashad</surname><given-names>JS</given-names></name><name><surname>Engar</surname><given-names>AJ</given-names></name><name><surname>Reynolds</surname><given-names>KR</given-names></name><name><surname>Anderson</surname><given-names>DJ</given-names></name><name><surname>Senina</surname><given-names>A</given-names></name><name><surname>Pomicter</surname><given-names>AD</given-names></name><name><surname>Arpin</surname><given-names>CC</given-names></name><name><surname>Ahmad</surname><given-names>S</given-names></name><etal/></person-group><article-title>Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia</article-title><source>Leukemia</source><year>2015</year><volume>29</volume><issue>3</issue><fpage>586</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">25134459</pub-id></element-citation></ref><ref id="R101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prost</surname><given-names>S</given-names></name><name><surname>Relouzat</surname><given-names>F</given-names></name><name><surname>Spentchian</surname><given-names>M</given-names></name><name><surname>Ouzegdouh</surname><given-names>Y</given-names></name><name><surname>Saliba</surname><given-names>J</given-names></name><name><surname>Massonnet</surname><given-names>G</given-names></name><name><surname>Beressi</surname><given-names>JP</given-names></name><name><surname>Verhoeyen</surname><given-names>E</given-names></name><name><surname>Raggueneau</surname><given-names>V</given-names></name><name><surname>Maneglier</surname><given-names>B</given-names></name><name><surname>Castaigne</surname><given-names>S</given-names></name><name><surname>Chomienne</surname><given-names>C</given-names></name><name><surname>Chretien</surname><given-names>S</given-names></name><name><surname>Rousselot</surname><given-names>P</given-names></name><name><surname>Leboulch</surname><given-names>P</given-names></name></person-group><article-title>Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists</article-title><source>Nature</source><year>2015</year><volume>525</volume><issue>7569</issue><fpage>380</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">26331539</pub-id></element-citation></ref><ref id="R102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Yin</surname><given-names>CC</given-names></name><name><surname>O'Brien</surname><given-names>S</given-names></name><name><surname>Cortes</surname><given-names>JE</given-names></name><name><surname>Jabbour</surname><given-names>E</given-names></name><name><surname>Breeden</surname><given-names>M</given-names></name><name><surname>Giles</surname><given-names>FJ</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Kantarjian</surname><given-names>HM</given-names></name></person-group><article-title>Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors</article-title><source>Cancer</source><year>2008</year><volume>113</volume><issue>5</issue><fpage>985</fpage><lpage>994</lpage><pub-id pub-id-type="pmid">18615627</pub-id></element-citation></ref><ref id="R103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullighan</surname><given-names>CG</given-names></name><name><surname>Williams</surname><given-names>RT</given-names></name><name><surname>Downing</surname><given-names>JR</given-names></name><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group><article-title>Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL</article-title><source>Genes &#x00026; development</source><year>2008</year><volume>22</volume><issue>11</issue><fpage>1411</fpage><lpage>1415</lpage><pub-id pub-id-type="pmid">18519632</pub-id></element-citation></ref><ref id="R104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>KR</given-names></name><name><surname>Carroll</surname><given-names>A</given-names></name><name><surname>Heerema</surname><given-names>NA</given-names></name><name><surname>Bowman</surname><given-names>WP</given-names></name><name><surname>Aledo</surname><given-names>A</given-names></name><name><surname>Slayton</surname><given-names>WB</given-names></name><name><surname>Sather</surname><given-names>H</given-names></name><name><surname>Devidas</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>HW</given-names></name><name><surname>Davies</surname><given-names>SM</given-names></name><name><surname>Gaynon</surname><given-names>PS</given-names></name><name><surname>Trigg</surname><given-names>M</given-names></name><name><surname>Rutledge</surname><given-names>R</given-names></name><name><surname>Jorstad</surname><given-names>D</given-names></name><name><surname>Winick</surname><given-names>N</given-names></name><name><surname>Borowitz</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031</article-title><source>Leukemia</source><year>2014</year><volume>28</volume><issue>7</issue><fpage>1467</fpage><lpage>1471</lpage><pub-id pub-id-type="pmid">24441288</pub-id></element-citation></ref><ref id="R105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biondi</surname><given-names>A</given-names></name><name><surname>Schrappe</surname><given-names>M</given-names></name><name><surname>De Lorenzo</surname><given-names>P</given-names></name><name><surname>Castor</surname><given-names>A</given-names></name><name><surname>Lucchini</surname><given-names>G</given-names></name><name><surname>Gandemer</surname><given-names>V</given-names></name><name><surname>Pieters</surname><given-names>R</given-names></name><name><surname>Stary</surname><given-names>J</given-names></name><name><surname>Escherich</surname><given-names>G</given-names></name><name><surname>Campbell</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>CK</given-names></name><name><surname>Vora</surname><given-names>A</given-names></name><name><surname>Arico</surname><given-names>M</given-names></name><name><surname>Rottgers</surname><given-names>S</given-names></name><name><surname>Saha</surname><given-names>V</given-names></name><name><surname>Valsecchi</surname><given-names>MG</given-names></name></person-group><article-title>Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study</article-title><source>Lancet Oncol</source><year>2012</year><volume>13</volume><issue>9</issue><fpage>936</fpage><lpage>945</lpage><pub-id pub-id-type="pmid">22898679</pub-id></element-citation></ref><ref id="R106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daver</surname><given-names>N</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Ravandi</surname><given-names>F</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>Garris</surname><given-names>R</given-names></name><name><surname>Jabbour</surname><given-names>E</given-names></name><name><surname>Garcia-Manero</surname><given-names>G</given-names></name><name><surname>Borthakur</surname><given-names>G</given-names></name><name><surname>Kadia</surname><given-names>T</given-names></name><name><surname>Rytting</surname><given-names>M</given-names></name><name><surname>Konopleva</surname><given-names>M</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>O'Brien</surname><given-names>S</given-names></name></person-group><article-title>Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia</article-title><source>Haematologica</source><year>2015</year><volume>100</volume><issue>5</issue><fpage>653</fpage><lpage>661</lpage><pub-id pub-id-type="pmid">25682595</pub-id></element-citation></ref><ref id="R107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravandi</surname><given-names>F</given-names></name><name><surname>O'Brien</surname><given-names>SM</given-names></name><name><surname>Cortes</surname><given-names>JE</given-names></name><name><surname>Thomas</surname><given-names>DM</given-names></name><name><surname>Garris</surname><given-names>R</given-names></name><name><surname>Faderl</surname><given-names>S</given-names></name><name><surname>Burger</surname><given-names>JA</given-names></name><name><surname>Rytting</surname><given-names>ME</given-names></name><name><surname>Ferrajoli</surname><given-names>A</given-names></name><name><surname>Wierda</surname><given-names>WG</given-names></name><name><surname>Verstovsek</surname><given-names>S</given-names></name><name><surname>Champlin</surname><given-names>R</given-names></name><name><surname>Kebriaei</surname><given-names>P</given-names></name><name><surname>McCue</surname><given-names>DA</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Jabbour</surname><given-names>E</given-names></name><etal/></person-group><article-title>Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia</article-title><source>Cancer</source><year>2015</year><volume>121</volume><issue>23</issue><fpage>4158</fpage><lpage>4164</lpage><pub-id pub-id-type="pmid">26308885</pub-id></element-citation></ref><ref id="R108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foa</surname><given-names>R</given-names></name><name><surname>Vitale</surname><given-names>A</given-names></name><name><surname>Vignetti</surname><given-names>M</given-names></name><name><surname>Meloni</surname><given-names>G</given-names></name><name><surname>Guarini</surname><given-names>A</given-names></name><name><surname>De Propris</surname><given-names>MS</given-names></name><name><surname>Elia</surname><given-names>L</given-names></name><name><surname>Paoloni</surname><given-names>F</given-names></name><name><surname>Fazi</surname><given-names>P</given-names></name><name><surname>Cimino</surname><given-names>G</given-names></name><name><surname>Nobile</surname><given-names>F</given-names></name><name><surname>Ferrara</surname><given-names>F</given-names></name><name><surname>Castagnola</surname><given-names>C</given-names></name><name><surname>Sica</surname><given-names>S</given-names></name><name><surname>Leoni</surname><given-names>P</given-names></name><name><surname>Zuffa</surname><given-names>E</given-names></name><etal/></person-group><article-title>Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia</article-title><source>Blood</source><year>2011</year><volume>118</volume><issue>25</issue><fpage>6521</fpage><lpage>6528</lpage><pub-id pub-id-type="pmid">21931113</pub-id></element-citation></ref><ref id="R109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiaretti</surname><given-names>S</given-names></name><name><surname>Foa</surname><given-names>R</given-names></name></person-group><article-title>Management of adult Ph-positive acute lymphoblastic leukemia</article-title><source>Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program</source><year>2015</year><volume>2015</volume><issue>1</issue><fpage>406</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">26637750</pub-id></element-citation></ref><ref id="R110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>EL</given-names></name><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Camidge</surname><given-names>DR</given-names></name><name><surname>Shaw</surname><given-names>AT</given-names></name><name><surname>Solomon</surname><given-names>B</given-names></name><name><surname>Maki</surname><given-names>RG</given-names></name><name><surname>Ou</surname><given-names>SH</given-names></name><name><surname>Dezube</surname><given-names>BJ</given-names></name><name><surname>Janne</surname><given-names>PA</given-names></name><name><surname>Costa</surname><given-names>DB</given-names></name><name><surname>Varella-Garcia</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>WH</given-names></name><name><surname>Lynch</surname><given-names>TJ</given-names></name><name><surname>Fidias</surname><given-names>P</given-names></name><name><surname>Stubbs</surname><given-names>H</given-names></name><name><surname>Engelman</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><issue>18</issue><fpage>1693</fpage><lpage>1703</lpage><pub-id pub-id-type="pmid">20979469</pub-id></element-citation></ref><ref id="R111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drilon</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Hasanovic</surname><given-names>A</given-names></name><name><surname>Suehara</surname><given-names>Y</given-names></name><name><surname>Lipson</surname><given-names>D</given-names></name><name><surname>Stephens</surname><given-names>P</given-names></name><name><surname>Ross</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>V</given-names></name><name><surname>Ginsberg</surname><given-names>M</given-names></name><name><surname>Zakowski</surname><given-names>MF</given-names></name><name><surname>Kris</surname><given-names>MG</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><name><surname>Rizvi</surname><given-names>N</given-names></name></person-group><article-title>Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas</article-title><source>Cancer Discov</source><year>2013</year><volume>3</volume><issue>6</issue><fpage>630</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">23533264</pub-id></element-citation></ref><ref id="R112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>B</given-names></name><name><surname>Wilner</surname><given-names>KD</given-names></name><name><surname>Shaw</surname><given-names>AT</given-names></name></person-group><article-title>Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer</article-title><source>Clin Pharmacol Ther</source><year>2014</year><volume>95</volume><issue>1</issue><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">24091716</pub-id></element-citation></ref><ref id="R113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katayama</surname><given-names>R</given-names></name><name><surname>Kobayashi</surname><given-names>Y</given-names></name><name><surname>Friboulet</surname><given-names>L</given-names></name><name><surname>Lockerman</surname><given-names>EL</given-names></name><name><surname>Koike</surname><given-names>S</given-names></name><name><surname>Shaw</surname><given-names>AT</given-names></name><name><surname>Engelman</surname><given-names>JA</given-names></name><name><surname>Fujita</surname><given-names>N</given-names></name></person-group><article-title>Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer</article-title><source>Clinical cancer research</source><year>2015</year><volume>21</volume><issue>1</issue><fpage>166</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">25351743</pub-id></element-citation></ref><ref id="R114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tibaldi</surname><given-names>C</given-names></name></person-group><article-title>Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small-cell lung cancer</article-title><source>Pharmacogenomics</source><year>2014</year><volume>15</volume><issue>2</issue><fpage>133</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">24444403</pub-id></element-citation></ref><ref id="R115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>HY</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Engstrom</surname><given-names>LD</given-names></name><name><surname>West</surname><given-names>M</given-names></name><name><surname>Appleman</surname><given-names>V</given-names></name><name><surname>Wong</surname><given-names>KA</given-names></name><name><surname>McTigue</surname><given-names>M</given-names></name><name><surname>Deng</surname><given-names>YL</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Brooun</surname><given-names>A</given-names></name><name><surname>Timofeevski</surname><given-names>S</given-names></name><name><surname>McDonnell</surname><given-names>SR</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name><name><surname>Falk</surname><given-names>MD</given-names></name><name><surname>Lappin</surname><given-names>PB</given-names></name><name><surname>Affolter</surname><given-names>T</given-names></name><etal/></person-group><article-title>PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations</article-title><source>Proc Natl Acad Sci U S A</source><year>2015</year><volume>112</volume><issue>11</issue><fpage>3493</fpage><lpage>3498</lpage><pub-id pub-id-type="pmid">25733882</pub-id></element-citation></ref><ref id="R116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>R</given-names></name></person-group><article-title>Drug resistance missense mutations in cancer are subject to evolutionary constraints</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>12</issue><fpage>e82059</fpage><pub-id pub-id-type="pmid">24376513</pub-id></element-citation></ref><ref id="R117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanizaki</surname><given-names>J</given-names></name><name><surname>Okamoto</surname><given-names>I</given-names></name><name><surname>Okabe</surname><given-names>T</given-names></name><name><surname>Sakai</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Kaneda</surname><given-names>H</given-names></name><name><surname>Takezawa</surname><given-names>K</given-names></name><name><surname>Kuwata</surname><given-names>K</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Hatashita</surname><given-names>E</given-names></name><name><surname>Nishio</surname><given-names>K</given-names></name><name><surname>Nakagawa</surname><given-names>K</given-names></name></person-group><article-title>Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer</article-title><source>Clinical cancer research</source><year>2012</year><volume>18</volume><issue>22</issue><fpage>6219</fpage><lpage>6226</lpage><pub-id pub-id-type="pmid">22843788</pub-id></element-citation></ref><ref id="R118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>S</given-names></name><name><surname>Nakade</surname><given-names>J</given-names></name><name><surname>Kita</surname><given-names>K</given-names></name><name><surname>Nakagawa</surname><given-names>T</given-names></name><name><surname>Nanjo</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Soda</surname><given-names>M</given-names></name><name><surname>Mano</surname><given-names>H</given-names></name><name><surname>Uenaka</surname><given-names>T</given-names></name><name><surname>Yano</surname><given-names>S</given-names></name></person-group><article-title>Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells</article-title><source>Clinical cancer research</source><year>2012</year><volume>18</volume><issue>13</issue><fpage>3592</fpage><lpage>3602</lpage><pub-id pub-id-type="pmid">22553343</pub-id></element-citation></ref><ref id="R119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voena</surname><given-names>C</given-names></name><name><surname>Di Giacomo</surname><given-names>F</given-names></name><name><surname>Panizza</surname><given-names>E</given-names></name><name><surname>D'Amico</surname><given-names>L</given-names></name><name><surname>Boccalatte</surname><given-names>FE</given-names></name><name><surname>Pellegrino</surname><given-names>E</given-names></name><name><surname>Todaro</surname><given-names>M</given-names></name><name><surname>Recupero</surname><given-names>D</given-names></name><name><surname>Tabbo</surname><given-names>F</given-names></name><name><surname>Ambrogio</surname><given-names>C</given-names></name><name><surname>Martinengo</surname><given-names>C</given-names></name><name><surname>Bonello</surname><given-names>L</given-names></name><name><surname>Pulito</surname><given-names>R</given-names></name><name><surname>Hamm</surname><given-names>J</given-names></name><name><surname>Chiarle</surname><given-names>R</given-names></name><name><surname>Cheng</surname><given-names>M</given-names></name><etal/></person-group><article-title>The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1</article-title><source>Oncogenesis</source><year>2013</year><volume>2</volume><fpage>e43</fpage><pub-id pub-id-type="pmid">23567620</pub-id></element-citation></ref><ref id="R120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katayama</surname><given-names>R</given-names></name><name><surname>Shaw</surname><given-names>AT</given-names></name><name><surname>Khan</surname><given-names>TM</given-names></name><name><surname>Mino-Kenudson</surname><given-names>M</given-names></name><name><surname>Solomon</surname><given-names>BJ</given-names></name><name><surname>Halmos</surname><given-names>B</given-names></name><name><surname>Jessop</surname><given-names>NA</given-names></name><name><surname>Wain</surname><given-names>JC</given-names></name><name><surname>Yeo</surname><given-names>AT</given-names></name><name><surname>Benes</surname><given-names>C</given-names></name><name><surname>Drew</surname><given-names>L</given-names></name><name><surname>Saeh</surname><given-names>JC</given-names></name><name><surname>Crosby</surname><given-names>K</given-names></name><name><surname>Sequist</surname><given-names>LV</given-names></name><name><surname>Iafrate</surname><given-names>AJ</given-names></name><name><surname>Engelman</surname><given-names>JA</given-names></name></person-group><article-title>Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers</article-title><source>Sci Transl Med</source><year>2012</year><volume>4</volume><issue>120</issue><fpage>120ra117</fpage></element-citation></ref><ref id="R121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>FH</given-names></name><name><surname>Johannessen</surname><given-names>CM</given-names></name><name><surname>Piccioni</surname><given-names>F</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Corsello</surname><given-names>SM</given-names></name><name><surname>Capelletti</surname><given-names>M</given-names></name><name><surname>Calles</surname><given-names>A</given-names></name><name><surname>Butaney</surname><given-names>M</given-names></name><name><surname>Sharifnia</surname><given-names>T</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Engelman</surname><given-names>JA</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><etal/></person-group><article-title>A functional landscape of resistance to ALK inhibition in lung cancer</article-title><source>Cancer Cell</source><year>2015</year><volume>27</volume><issue>3</issue><fpage>397</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">25759024</pub-id></element-citation></ref><ref id="R122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pennacchietti</surname><given-names>S</given-names></name><name><surname>Cazzanti</surname><given-names>M</given-names></name><name><surname>Bertotti</surname><given-names>A</given-names></name><name><surname>Rideout</surname><given-names>WM</given-names><suffix>3rd</suffix></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Gyuris</surname><given-names>J</given-names></name><name><surname>Perera</surname><given-names>T</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name><name><surname>Trusolino</surname><given-names>L</given-names></name><name><surname>Michieli</surname><given-names>P</given-names></name></person-group><article-title>Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs</article-title><source>Cancer Res</source><year>2014</year><volume>74</volume><issue>22</issue><fpage>6598</fpage><lpage>6609</lpage><pub-id pub-id-type="pmid">25217525</pub-id></element-citation></ref><ref id="R123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crescenzo</surname><given-names>R</given-names></name><name><surname>Inghirami</surname><given-names>G</given-names></name></person-group><article-title>Anaplastic lymphoma kinase inhibitors</article-title><source>Current opinion in pharmacology</source><year>2015</year><volume>23</volume><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">26051994</pub-id></element-citation></ref><ref id="R124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuoka</surname><given-names>H</given-names></name><name><surname>Kurata</surname><given-names>T</given-names></name><name><surname>Okamoto</surname><given-names>I</given-names></name><name><surname>Kaneda</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Nakagawa</surname><given-names>K</given-names></name></person-group><article-title>Clinical response to crizotinib retreatment after acquisition of drug resistance</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><issue>19</issue><fpage>e322</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">23715571</pub-id></element-citation></ref><ref id="R125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chmielecki</surname><given-names>J</given-names></name><name><surname>Foo</surname><given-names>J</given-names></name><name><surname>Oxnard</surname><given-names>GR</given-names></name><name><surname>Hutchinson</surname><given-names>K</given-names></name><name><surname>Ohashi</surname><given-names>K</given-names></name><name><surname>Somwar</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Amato</surname><given-names>KR</given-names></name><name><surname>Arcila</surname><given-names>M</given-names></name><name><surname>Sos</surname><given-names>ML</given-names></name><name><surname>Socci</surname><given-names>ND</given-names></name><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>de Stanchina</surname><given-names>E</given-names></name><name><surname>Ginsberg</surname><given-names>MS</given-names></name><name><surname>Thomas</surname><given-names>RK</given-names></name><name><surname>Kris</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling</article-title><source>Sci Transl Med</source><year>2011</year><volume>3</volume><issue>90</issue><fpage>90ra59</fpage></element-citation></ref><ref id="R126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voena</surname><given-names>C</given-names></name><name><surname>Menotti</surname><given-names>M</given-names></name><name><surname>Mastini</surname><given-names>C</given-names></name><name><surname>Di Giacomo</surname><given-names>F</given-names></name><name><surname>Longo</surname><given-names>DL</given-names></name><name><surname>Castella</surname><given-names>B</given-names></name><name><surname>Merlo</surname><given-names>ME</given-names></name><name><surname>Ambrogio</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Minero</surname><given-names>VG</given-names></name><name><surname>Poggio</surname><given-names>T</given-names></name><name><surname>Martinengo</surname><given-names>C</given-names></name><name><surname>D'Amico</surname><given-names>L</given-names></name><name><surname>Panizza</surname><given-names>E</given-names></name><name><surname>Mologni</surname><given-names>L</given-names></name><name><surname>Cavallo</surname><given-names>F</given-names></name><etal/></person-group><article-title>Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors</article-title><source>Cancer immunology research</source><year>2015</year><volume>3</volume><issue>12</issue><fpage>1333</fpage><lpage>1343</lpage><pub-id pub-id-type="pmid">26419961</pub-id></element-citation></ref><ref id="R127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subbiah</surname><given-names>V</given-names></name><name><surname>Berry</surname><given-names>J</given-names></name><name><surname>Roxas</surname><given-names>M</given-names></name><name><surname>Guha-Thakurta</surname><given-names>N</given-names></name><name><surname>Subbiah</surname><given-names>IM</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>McMahon</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>V</given-names></name><name><surname>Cascone</surname><given-names>T</given-names></name><name><surname>Pai</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Heymach</surname><given-names>JV</given-names></name></person-group><article-title>Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases</article-title><source>Lung Cancer</source><year>2015</year><volume>89</volume><issue>1</issue><fpage>76</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">25982012</pub-id></element-citation></ref><ref id="R128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Soler</surname><given-names>R</given-names></name><name><surname>Chachoua</surname><given-names>A</given-names></name><name><surname>Hammond</surname><given-names>LA</given-names></name><name><surname>Rowinsky</surname><given-names>EK</given-names></name><name><surname>Huberman</surname><given-names>M</given-names></name><name><surname>Karp</surname><given-names>D</given-names></name><name><surname>Rigas</surname><given-names>J</given-names></name><name><surname>Clark</surname><given-names>GM</given-names></name><name><surname>Santabarbara</surname><given-names>P</given-names></name><name><surname>Bonomi</surname><given-names>P</given-names></name></person-group><article-title>Determinants of tumor response and survival with erlotinib in patients with non&#x02014;small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><issue>16</issue><fpage>3238</fpage><lpage>3247</lpage><pub-id pub-id-type="pmid">15310767</pub-id></element-citation></ref><ref id="R129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>O</given-names></name><name><surname>Dumlao</surname><given-names>TL</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>O'Brien</surname><given-names>S</given-names></name><name><surname>Garcia-Manero</surname><given-names>G</given-names></name><name><surname>Faderl</surname><given-names>S</given-names></name><name><surname>Jorgensen</surname><given-names>J</given-names></name><name><surname>Luthra</surname><given-names>R</given-names></name><name><surname>Garris</surname><given-names>R</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Kebriaei</surname><given-names>P</given-names></name><name><surname>Champlin</surname><given-names>R</given-names></name><name><surname>Jabbour</surname><given-names>E</given-names></name><name><surname>Burger</surname><given-names>J</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>Ravandi</surname><given-names>F</given-names></name></person-group><article-title>Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia</article-title><source>American journal of hematology</source><year>2014</year><volume>89</volume><issue>3</issue><fpage>282</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">24779033</pub-id></element-citation></ref><ref id="R130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>RD</given-names></name></person-group><article-title>Immunologic and clinical effects of targeting PD-1 in lung cancer</article-title><source>Clin Pharmacol Ther</source><year>2014</year><volume>96</volume><issue>2</issue><fpage>214</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">24690569</pub-id></element-citation></ref><ref id="R131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benyamini</surname><given-names>N</given-names></name><name><surname>Rowe</surname><given-names>JM</given-names></name></person-group><article-title>Is there a role for allogeneic transplantation in chronic myeloid leukemia?</article-title><source>Expert Rev Hematol</source><year>2013</year><volume>6</volume><issue>6</issue><fpage>759</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">24219552</pub-id></element-citation></ref><ref id="R132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>H</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name></person-group><article-title>Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer</article-title><source>Translational lung cancer research</source><year>2015</year><volume>4</volume><issue>1</issue><fpage>82</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">25806348</pub-id></element-citation></ref><ref id="R133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>BK</given-names></name><name><surname>Yang</surname><given-names>JY</given-names></name><name><surname>Dong</surname><given-names>JX</given-names></name><name><surname>Ji</surname><given-names>ZS</given-names></name><name><surname>Si</surname><given-names>HY</given-names></name><name><surname>Wang</surname><given-names>WL</given-names></name><name><surname>Huang</surname><given-names>RQ</given-names></name></person-group><article-title>Meta-analysis of seven randomized control trials to assess the efficacy and toxicity of combining EGFR-TKI with chemotherapy for patients with advanced NSCLC who failed first-line treatment</article-title><source>Asian Pacific journal of cancer prevention</source><year>2015</year><volume>16</volume><issue>7</issue><fpage>2915</fpage><lpage>2921</lpage><pub-id pub-id-type="pmid">25854383</pub-id></element-citation></ref><ref id="R134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>RR</given-names></name><name><surname>Hilbert</surname><given-names>ML</given-names></name><name><surname>Dixon-Moh</surname><given-names>YN</given-names></name><name><surname>Decandio</surname><given-names>M</given-names></name><name><surname>Vandergrift</surname><given-names>WA</given-names><suffix>3rd</suffix></name><name><surname>Banik</surname><given-names>NL</given-names></name><name><surname>Lindhorst</surname><given-names>SM</given-names></name><name><surname>Cachia</surname><given-names>D</given-names></name><name><surname>Varma</surname><given-names>AK</given-names></name><name><surname>Patel</surname><given-names>SJ</given-names></name><name><surname>Giglio</surname><given-names>P</given-names></name></person-group><article-title>Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma</article-title><source>Cancer growth and metastasis</source><year>2015</year><volume>8</volume><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">26648752</pub-id></element-citation></ref><ref id="R135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appelmann</surname><given-names>I</given-names></name><name><surname>Rillahan</surname><given-names>CD</given-names></name><name><surname>de Stanchina</surname><given-names>E</given-names></name><name><surname>Carbonetti</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group><article-title>Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL</article-title><source>Blood</source><year>2015</year><volume>125</volume><issue>9</issue><fpage>1444</fpage><lpage>1451</lpage><pub-id pub-id-type="pmid">25499760</pub-id></element-citation></ref><ref id="R136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leder</surname><given-names>K</given-names></name><name><surname>Pitter</surname><given-names>K</given-names></name><name><surname>Laplant</surname><given-names>Q</given-names></name><name><surname>Hambardzumyan</surname><given-names>D</given-names></name><name><surname>Ross</surname><given-names>BD</given-names></name><name><surname>Chan</surname><given-names>TA</given-names></name><name><surname>Holland</surname><given-names>EC</given-names></name><name><surname>Michor</surname><given-names>F</given-names></name></person-group><article-title>Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules</article-title><source>Cell</source><year>2014</year><volume>156</volume><issue>3</issue><fpage>603</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">24485463</pub-id></element-citation></ref><ref id="R137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aparicio</surname><given-names>S</given-names></name><name><surname>Hidalgo</surname><given-names>M</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name></person-group><article-title>Examining the utility of patient-derived xenograft mouse models</article-title><source>Nature reviews Cancer</source><year>2015</year><volume>15</volume><issue>5</issue><fpage>311</fpage><lpage>316</lpage></element-citation></ref><ref id="R138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertotti</surname><given-names>A</given-names></name><name><surname>Papp</surname><given-names>E</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Adleff</surname><given-names>V</given-names></name><name><surname>Anagnostou</surname><given-names>V</given-names></name><name><surname>Lupo</surname><given-names>B</given-names></name><name><surname>Sausen</surname><given-names>M</given-names></name><name><surname>Phallen</surname><given-names>J</given-names></name><name><surname>Hruban</surname><given-names>CA</given-names></name><name><surname>Tokheim</surname><given-names>C</given-names></name><name><surname>Niknafs</surname><given-names>N</given-names></name><name><surname>Nesselbush</surname><given-names>M</given-names></name><name><surname>Lytle</surname><given-names>K</given-names></name><name><surname>Sassi</surname><given-names>F</given-names></name><name><surname>Cottino</surname><given-names>F</given-names></name><name><surname>Migliardi</surname><given-names>G</given-names></name><etal/></person-group><article-title>The genomic landscape of response to EGFR blockade in colorectal cancer</article-title><source>Nature</source><year>2015</year><volume>526</volume><issue>7572</issue><fpage>263</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">26416732</pub-id></element-citation></ref><ref id="R139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Korn</surname><given-names>JM</given-names></name><name><surname>Ferretti</surname><given-names>S</given-names></name><name><surname>Monahan</surname><given-names>JE</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Schnell</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Balbin</surname><given-names>OA</given-names></name><name><surname>Barbe</surname><given-names>S</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Casey</surname><given-names>F</given-names></name><name><surname>Chatterjee</surname><given-names>S</given-names></name><name><surname>Chiang</surname><given-names>DY</given-names></name><etal/></person-group><article-title>High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response</article-title><source>Nature medicine</source><year>2015</year><volume>21</volume><issue>11</issue><fpage>1318</fpage><lpage>1325</lpage></element-citation></ref><ref id="R140"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>DD</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Gu</surname><given-names>Q</given-names></name><name><surname>Lira</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Qian</surname><given-names>M</given-names></name><name><surname>Sheng</surname><given-names>W</given-names></name><name><surname>Ozeck</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>KX</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>SH</given-names></name><name><surname>Christensen</surname><given-names>J</given-names></name><etal/></person-group><article-title>HIP1-ALK, a novel ALK fusion variant that responds to crizotinib</article-title><source>J Thorac Oncol</source><year>2014</year><volume>9</volume><issue>3</issue><fpage>285</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">24496003</pub-id></element-citation></ref><ref id="R141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>M</given-names></name><name><surname>Quail</surname><given-names>MR</given-names></name><name><surname>Gingrich</surname><given-names>DE</given-names></name><name><surname>Ott</surname><given-names>GR</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Wan</surname><given-names>W</given-names></name><name><surname>Albom</surname><given-names>MS</given-names></name><name><surname>Angeles</surname><given-names>TS</given-names></name><name><surname>Aimone</surname><given-names>LD</given-names></name><name><surname>Cristofani</surname><given-names>F</given-names></name><name><surname>Machiorlatti</surname><given-names>R</given-names></name><name><surname>Abele</surname><given-names>C</given-names></name><name><surname>Ator</surname><given-names>MA</given-names></name><name><surname>Dorsey</surname><given-names>BD</given-names></name><name><surname>Inghirami</surname><given-names>G</given-names></name><name><surname>Ruggeri</surname><given-names>B</given-names></name></person-group><article-title>CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers</article-title><source>Mol Cancer Ther</source><year>2011</year><volume>11</volume><issue>3</issue><fpage>670</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">22203728</pub-id></element-citation></ref><ref id="R142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>K</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>F</given-names></name><name><surname>Lan</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>N</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>B</given-names></name><name><surname>Cui</surname><given-names>B</given-names></name><name><surname>Teng</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>F</given-names></name></person-group><article-title>Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases</article-title><source>International journal of molecular medicine</source><year>2012</year><volume>30</volume><issue>1</issue><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">22505231</pub-id></element-citation></ref></ref-list></back></article>